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Salmonella enterica continues to be a significant public health concern,
causing an estimated 93.8 million cases of non-typhoidal salmonellosis and 21
million cases of typhoid fever worldwide each year. There are thousands of
Salmonella enterica serovars, some with a very specific host set, and others that
cause disease in rodents, birds, livestock, domestic fowl, and humans alike. In
recent years, there has been much progress in the delineation of Salmonella
infection, with the goal of understanding Salmonella pathogenesis at the
molecular level. Salmonella produces many different effector proteins capable of
interacting with and altering numerous biological pathways in the host – enabling
host invasion and intracellular survival as well as dissemination and
transmission.
We used X-ray crystallography to characterize Gifsy-2 Gene E (GtgE), an
effector protease from broad-host serovars of Salmonella, that affords these
serovars, at least in part, with the ability to maintain a diverse host repertoire.
GtgE modulates vesicular trafficking of the Salmonella-containing vacuole by
cleaving Rab GTPases, Rab29, Rab32, and Rab38, thereby preventing the
delivery of antimicrobial products to the vacuole. In order to gain an
understanding of GtgE’s proteolytic mechanism, we determined the structure of

GtgE to 1.65Å using single-wavelength anomalous diffraction, and through
structure-based mutagenesis and in vitro activity assays, we established the
catalytic triad of GtgE, Cys45-His151-Asp169. We also examined a panel of
cysteine protease inhibitors and found that N-ethylmaleimide, chymostatin, and
antipain were capable of inhibiting GtgE activity in vitro. Furthermore, through
work with the catalytically inactive mutant of GtgE (GtgE-C45A), we were able to
identify the conditions necessary to form a stable complex between GtgE and
Rab38, which may prove useful for further structural work and reveal the nature
of GtgE’s interaction with its Rab GTPase substrates.
Additionally, we investigated SipC, a Salmonella translocase protein with
two effector domains – an N-terminal actin bundling domain and a C-terminal
actin nucleation domain. We sought to define minimal constructs of these
effector domains for crystallization studies, and obtained needle-like spherulites
with the C-terminal domain. We also showed that mouse Exo70 is able to pulldown the C-terminal domain of SipC from cell lysate. Finally, we examined
Salmonella effector AvrA, which has been attributed with having deubiquitinase
and acetyltransferase activity, although its role in Salmonella pathogenesis
remains poorly understood. We determined a minimal construct of AvrA that
contains the proposed catalytic triad, and through a yeast two-hybrid experiment,
identified ARFGEF2 as a potential interacting partner for AvrA.
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CHAPTER 1. INTRODUCTION
1.1 Salmonella enterica

Salmonella enterica (S. enterica) is a rod-shaped, flagellated, Gram-negative
bacterium comprised of six subspecies [1]. Of these subspecies, only one,
Salmonella enterica subspecies enterica, is capable of causing disease in
vertebrate animals [1]. S. enterica subspecies enterica is further divided into
thousands of serovars distinguished by the antigenic polymorphisms of their
flagellar, carbohydrate, and lipopolysaccharide structures [2, 3]. These serovars
vary in their host specificity. Salmonella enterica serovar typhimurium (S.
typhimurium) is a broad-host serovar that is capable of infecting a wide range of
hosts. On the other end of the spectrum, Salmonella enterica serovar typhi (S.
typhi) is a human-adapted serovar, only causing disease in higher primates [4].
Host-specificity is believed to have evolved through the acquisition of new
genetic material via horizontal gene transfer and loss of functional genes through
genome degradation [5]. Genetic degradation, which involves the loss of genetic
information by gene deletion or pseudogene formation, is evident in strains of S.
typhi; 210 pseudogenes have been identified in S. typhi, while only 39
pseudogenes are present in S. typhimurium [4, 6-9].
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1.2 Pathogenesis

S. enterica infection can manifest itself as gastroenteritis, Typhoid
(enteric) fever, bacteremia, or chronic asymptomatic carriage [2]. In humans, the
severity of disease caused by S. enterica subspecies enterica varies based on
host health as well as the identity of the infecting serovar [3]. Nontyphoidal
Salmonella poses a considerable global health threat, and in 2010, there were
93.8 million cases estimated worldwide, of which approximately 155,000 resulted
in death [10]. Of the more than 21 million cases of typhoid fever reported
worldwide each year, upwards of 200,000 result in death, mostly in
underdeveloped countries [11]. Those infected with S. typhi are prone to
symptom relapse, and multidrug-resistant strains of S. typhi capable of infecting
otherwise healthy individuals are widespread, making S. typhi a significant
global-health concern [11-13].

In humans, S. enterica is predominantly acquired through fecal-oral
transmission, typically via the ingestion of contaminated food or water. S.
enterica is able to survive the low pH of the stomach, going on to colonize the
endothelial cells of the gastrointestinal tract [14]. Other S. enterica targets
include: macrophages, neutrophils, monocytes, dendritic cells, granulocytes, M
cells, B cells, and T cells [15]. Infection of the gut epithelial cells is known as
gastroenteritis, and accounts for roughly 26% of food poisoning cases in the
United States [14, 16]. Gastroenteritis is characterized by the acute onset of
!
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fever, chills, nausea, vomiting, abdominal cramping, and diarrhea [17]. Although
this infection is usually self-limiting, it can cause death in infants, the elderly, and
immunocompromised individuals [17].

1.2.1 Salmonella Pathogenicity Island-1: Intestinal Invasion

Before host cell invasion can occur, the bacterial cells adhere to the
intestinal epithelial cell surface using fimbriae, which are short, proteinaceous
structures extending from the bacterial surface that mediate attachment and can
confer attachment specificity [3, 14]. This adherence is reversible and in order to
irreversibly dock to and invade the host, Salmonella relies on the actions of
various proteins encoded by Salmonella pathogenicity islands, plasmids,
functional prophages, and phage remnants [18, 19]. Salmonella pathogenicity
islands are large, virulence factor-containing segments of DNA that are inserted
into chromosomal DNA, usually flanked by direct repeats and associated with
tRNA loci and insertion sequence (IS) elements [3, 20]. These pathogenicity
islands often contain mobility genes, such as integrases, transposases, IS
elements, and origins of plasmid replication, and have a lower G-C content,
roughly 37-47%, than is typical for bacterial chromosomal DNA, which has a 52%
G-C content [20]. Salmonella pathogenicity island I (SPI-1) is activated upon
docking and contains the genetic information necessary to produce and
assemble a type III secretion system (T3SS1) [2].
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Figure 1. The type III secretion system. The T3SS apparatus is comprised of
an inner (orange) and outer (red) ring that allow for passage through the inner
and outer bacterial membranes, and are linked by a neck domain (blue). The
needle (green) is anchored at the base of the neck via the inner rod, and extends
from the surface of the bacterial cell [21]. The translocon pore (purple) is formed
by an oligomerization of two bacterial effector/translocase proteins. This system
creates a pathway through which bacterial effector proteins can travel from the
bacterial cytoplasm into the host. EM images adapted from Schraidt, et al. and
Kosarewicz, et al. [22, 23].
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T3SS1 is a needle-like structure, often referred to as the injectisome, that
serves as a molecular syringe with the ability to deliver bacterial effector proteins
directly into the host cell (Fig. 1). T3SS1 is one of at least six different secretion
systems found in Gram-negative bacteria, and is believed to be evolutionarily
related to the bacterial flagellum [24]. The needle apparatus is composed of four
main parts: inner rings, a membrane-spanning neck, outer rings, and an external
needle complex (Fig. 1). In addition to these components, which are physically
associated with the bacterial cell, T3SS1 also includes a pore complex, the
translocon, that assembles within the host cell membrane [25]. Taken together,
the T3SS1 components create a pathway through which effector proteins,
proteins that possess the ability to modulate cellular mechanisms in the host, can
travel from the bacterial cytoplasm into the host cytoplasm.

An alternative hypothesis for effector translocation, in which the T3SS
effector mechanism functions similarly to the AB toxin delivery system, was
recently proposed by Edgren, et al. [26]. The authors suggest a two-step model
for translocation of effector proteins that entails: first, the secretion of
translocases and effectors; and second, the translocation of effectors into the
host cell upon host cell contact. Translocation is predicted to occur in an AB
toxin-like fashion, where the translocase acts as the pore-forming B subunit and
the effector functions as the catalytic A subunit. In this model, the needle
complex serves as a sensory structure used to identify the host cell, and as a
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pathway for the extracellular secretion of effectors [26]. This translocation
mechanism is based on data gathered on Yersinia, another bacterial species
utilizing a T3SS, showing that both Yersinia Yop translocases and effector
proteins are present on the bacterial surface prior to host cell contact [27], and
that a complex of translocases YopB and YopD with effector YopE occurs
extracellularly, prior to host invasion [28]. Further support has come from a study
by Rosqvist, et al. that identifies two Yersinina effectors, YopE and YopD, as
having AB toxin activity [29]. However, it remains unclear whether the proposed
AB toxin-like translocation mechanism applies only to Yersinia or if it can be
extended to all T3SS-utilizing bacteria as well. To date, translocase homologs in
Shigella and Salmonella have not been shown to have AB toxin activity, nor have
extracellular intermediate translocase-effector complexes been identified in
Shigella or Salmonella, although the translocase proteins do appear to associate
prior to translocon formation [30, 31]. Since direct evidence for the translocon is
lacking and the methods of translocase insertion and translocon formation remain
unknown, additional studies will be required in order to discern the true mode of
effector translocation.

Once translocated into the host, effector proteins interact with and alter
host pathways in a variety of ways. The initial wave of delivered effectors
performs various functions aimed at encouraging host uptake of the bacterial cell,
including stimulating GTPase activation and actin polymerization in order to
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induce the phagocytic engulfment of the Salmonella cell by the host [32]. As the
bacterial cell enters the host it becomes enveloped in a membrane-bound
vesicle, termed the Salmonella-containing vacuole (SCV), which undergoes a
maturation process and serves as the site of replication for the bacterium [33]
(Fig. 2).

Salm

Effector !
proteins!

onell

a!

SCV!
Host!

Figure 2. Salmonella enters the host cell. In order to invade its host,
Salmonella injects effector proteins into the host cell that stimulate the
bacterium’s uptake and enable it to survive and replicate inside the Salmonellacontaining vacuole (SCV).
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1.2.2 Salmonella Pathogenicity Island-2: Survival and Replication

Upon internalization, Salmonella begins expressing SPI-2-encoded
effector proteins in response to various environmental cues, such as low
osmolarity, acidification of the SCV, and decreased levels of certain nutrients
[34]. SPI-2 also encodes a second T3SS, T3SS2, which is structurally similar to
that of T3SS1. T3SS2 functions to transport bacterial effectors across the SCV
membrane and into the host cytoplasm where they can then interact with their
targets [14]. Salmonella utilizes a variety of different effector proteins to
attenuate the host’s defense mechanisms and increase its chances for survival
and replication inside the SCV [3].

T3SS2 also plays a role in the biogenesis of the SCV, which is a modified
phagosome with characteristics of a late endosome [35]. The eukaryotic
endocytic pathway is a degradation pathway that involves endosome maturation
and subsequent development into a functional hydrolytic phagolysosome for
cargo degradation [36]. In its early stage of biogenesis, the SCV shows the
transient presence of early endocytic markers, mainly EEA1, Rab GTPase 5, and
transferrin receptor [37]. These markers are replaced by the late endocytic
indicators: lysosomal-associated membrane proteins (LAMP) 1 and 2, vacuolar
ATPase (vATPase), and cholesterol [36, 38, 39]. LAMP1 and LAMP2 are
integral membrane proteins involved in membrane fusion and the biogenesis of
lysosomes, and are often present in late endosomes. V-ATPase causes the
!
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acidification of the SCV lumen, and during this stage, the SCV moves into a
juxtanuclear position proximal to the microtubule organizing center [40-42]. At
this point in development, Salmonella begins replicating inside the SCV, and
extensive membrane tubules, or Salmonella-induced filaments, begin to form,
originating from the SCV and projecting throughout the host cell [43, 44]. The
SCV is able to circumvent the degradation step of the endocytic pathway by
preventing the assembly of a functional hydrolytic phagolysosome [36].

1.2.3 Dissemination and Transmission

In order to continue propagation, S. enterica must move from one host to
the next. There are several mechanisms by which Salmonella can cause host
cell death and enable its escape from the host: epithelial cell apoptosis, rapid
T3SS1-dependent pyroptosis, and delayed T3SS2-dependent macrophage
pyroptosis [45]. Apoptosis of the host is a form of programmed cell death that
involves the dismantling of the cell by executioner caspases and phagocytosis of
the resulting apoptotic bodies by phagocytic cells without eliciting an
inflammatory response [45]. During the replication phase, Salmonella is able to
delay apoptosis for 12-18 hours in its epithelial host, creating a more stable
intracellular environment for ample proliferation, and when ready to leave the
host, the bacterium triggers apoptosis in epithelial cells through the actions of
T3SS1 and T3SS2 effectors [18, 46, 47].
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In macrophages, S. enterica can cause either a rapid T3SS1-dependent or
a delayed T3SS2-dependent programmed cell death known as pyroptosis [18].
Unlike apoptosis, pyroptosis is a proinflammatory pathway dependent on
caspase-1 activation, which mounts an immune response that terminates in cell
lysis [45, 48]. During rapid T3SS1-dependent pyroptosis, several T3SS1
effectors function together with caspase-1 to cause cell lysis within 2-3 hours
post-infection [49]. In contrast, delayed T3SS2-dependent pyroptosis relies on
specific T3SS2 effector proteins and caspase-1 activity to cause apoptosis-like
macrophage death 18-24 hours post-infection [50]. Salmonella employs rapid or
delayed pyroptosis depending on the given physiological conditions, tissue
location, and stage of infection [49]. Rapid pyroptosis occurs during the intestinal
phase of infection, and may aid in systemic spread of infection through the
recruitment of phagocytes and increased inflammation [49]. Once systemic,
delayed pyroptosis is utilized for intracellular spread at the site of infection by
stimulating the formation of Salmonella-containing apoptotic bodies that are then
engulfed by neighboring macrophages [49, 50]. Through these cell death
mechanisms, S. enterica is able to spread between cells within an organism as
well as propagate itself between organisms via fecal-oral transmission.

!

10!

1.2.4 S. typhi Pathogenesis

In humans, S. typhi infection poses a much more serious health concern
than does S. typhimurium, as it causes a systemic infection even in healthy
individuals. This systemic infection, Typhoid fever, requires a 1-3 week
incubation period, in which time the bacteria travels through the bloodstream,
predominately targeting the liver, spleen, gall bladder, and bone marrow [19, 51].
The underlying mechanistic differences responsible for the dramatic contrast in
S. typhimurium and S. typhi disease outcome are largely unknown. Both
pathogens enter the human host orally and initially reside and replicate inside the
SCV.

Unlike S. typhimurium, which stimulates a substantial neutrophil influx into
the intestines and is accompanied by diarrhea, S. typhi infection does not lead to
significant intestinal inflammation and only a third of cases develop diarrhea [4].
S. typhi expresses the Vi antigen, a capsular polysaccharide, on its surface
during intestinal infection. The Vi antigen down-regulates the Toll-like receptormediated host response that induces neutrophil infiltration; thus, through Vi
antigen expression, S. typhi is able to colonize deeper body tissues [52-54].

Another distinguishing feature of S. typhi is that it produces and secretes a
typhoid toxin, which is similar to the cytolethal distending toxin (CDT) produced
by many other Gram-negative bacterial pathogens [55]. Typhoid toxin, like CDT,
!
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is an AB toxin that possesses DNase and ADP-ribosyl transferase activities and
is capable of translocating to the host nucleus, making double-strand breaks in
DNA and ultimately leading to cell cycle arrest and apoptosis in the host [55-57].
This toxin is expressed once S. typhi reaches an intracellular location, and it is
then transported outside the host through a series of vesicular transport
intermediates where it is able to induce apoptosis in infected and uninfected
neighboring cells [56, 58, 59]. By causing apoptosis in the host tissue, CDT
toxins enable bacterial colonization, persistent infection, and chronic disease
[57]. S. typhi is able to persist in infected tissues and evade immune defenses
by residing inside host cells that lack CDT receptors, and therefore, are not
susceptible to typhoid toxin action [58]. This persistence allows S. typhi to infect
humans for extended periods of time, and even for life, if the infection goes
untreated.

1.3 Gifsy-2 Gene E Effector Protein

Another distinguishing factor between S. typhimurium and S. typhi is the
presence of effector protease Gifsy-2 Gene E (GtgE) [56, 60]. GtgE, which is
required for full virulence of S. typhimurium, is one of two virulent genes located
on the Gifsy-2 bacteriophage and is secreted in a SPI-1 T3SS-dependent manner
[56, 61]. GtgE proteolytically cleaves and inactivates its Rab GTPase substrates
(Rab29, Rab32, Rab38), enabling S. typhimurium to evade the host’s
antimicrobial defenses as it carries out its lifecycle within the SCV. Expression of
!
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GtgE in S. typhi allows the pathogen to overcome some of its host restriction
barrier to infect mouse macrophages, which is likely due to the pathogen’s ability
to better elude host microbial defenses [60]. In wild-type S. typhi infection, the
recruitment of Rab29 to the SCV aids in the formation of toxin transport
intermediates, ultimately facilitating a systemic S. typhi infection [56].

As GtgE’s biological role has only recently been discerned, little is
understood as to how the protease performs its catalytic function. GtgE is a
26kD protein, 228 residues in length, with predicted C-terminal homology to
known papain-like cysteine proteases as determined by HHpred [62]. This Cterminal homology does not span the entire active site of GtgE, making functional
predictions about the enzyme fairly ambiguous. Through our structural and
biochemical studies detailed in this work, we have determined that GtgE
functions as a cysteine protease and have identified the catalytic residues
necessary for GtgE’s activity.
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1.4 Rab GTPases

GDP!

GTP!
GEF!

GDF!

GDP!

Rab! Effector!

Rab!

GTP!
GAP!
Pi!

Mem

bran

e!

GDI!

Figure 3. The activity cycle of Rab GTPases. Rab GTPases cycle
between GDP- and GTP-bound states with the aid of GTPase-activating
proteins (GAPs) and guanine nucleotide exchange factors (GEFs). The GTPbound state primes the Rab for interaction with its specific, membranelocalized cellular target. Figure adapted from Stenmark, et al. and Ebine, et
al. [63, 64].

In humans, the Rab GTPase family, which falls within the Ras superfamily
of small G proteins, contains more than 60 members that are localized to distinct
intracellular membranes based on the sequence variation and prenylation of their
C-terminal domain [65]. Rab GTPases cycle between inactive and active states,
depending on whether they are bound to GDP or GTP, to participate in the
!
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regulation of membrane trafficking, cell growth, and differentiation (Fig. 3) [65,
66]. Although Rabs have intrinsic GTPase activity, they require the aid of several
different interacting partners for adequate function [63]. The Rab activity cycle
begins upon prenylation and consequent delivery of the Rab to its target
membrane by accessory factors known as Rab escort proteins (REPs) [67].
Nucleotide exchange, GDP to GTP, and activation of Rab is facilitated by
guanine nucleotide exchange factors (GEFs), which are unique to each Rab [63].
GTPase-activating proteins (GAPs) accelerate the hydrolysis of GTP by Rab,
stimulating the given downstream effect [68, 69]. Following hydrolysis, the Rab is
bound to GDP and the GAP is replaced by a GDP dissociation inhibitor (GDI),
which displaces Rab from the membrane and sequesters it in the cytoplasm until
the next transport cycle begins [67].

Rab GTPases are typically small proteins, roughly 20-25kD, and share an
overall fold containing a six-stranded β sheet surrounded by five α helices [70].
The residues responsible for interacting with the guanine nucleotide and
magnesium ion, an essential cofactor for nucleotide binding, reside in the loop
regions connecting the β strands and α helices [64, 71]. The nucleotide-binding
pocket on these Rab proteins is formed by two highly conserved regions termed
Switch I and Switch II (Fig. 4A). These regions confer functional specificity to the
Rabs and serve as recognition sites for effector proteins because they make
dramatic conformational changes based on the identity of the bound nucleotide
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[72, 73]. GtgE cleaves its Rab substrate between a glycine and valine located
within the switch I region (Fig. 4B) and in doing so, presumably destroys the
nucleotide-binding pocket and inactivates the GTPase.

A!

Switch I!

Rab29
Rab32
Rab38

1!
1!
1!

cons !

1!

57!
75!
59!
75!

Switch II!
Rab29
Rab32
Rab38

58!
76!
60!

132!
150!
134!

cons

76!

150!

Rab29 133!
Rab32 151!
Rab38 135!

199!
220!
206!

cons

225!

151!

Rab29 100!
Rab32 221!
Rab38 207!

203!
225!
211!

cons

230!

226!

B!

Figure 4. The Rab GTPase substrates. (A) The alignment of full-length
Rab29, Rab32, and Rab38. Sequence homology is depicted on a color scale
ranging from red (high homology) to blue (low homology). Key structural
motifs, Switch I and Switch II, are indicated. Alignment generated in T-Coffee
[74]. (B) The GtgE cleavage site of Rab38, TIGVDF, which corresponds to
residues 41-46. GtgE cleaves between Gly43 and Val44.
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GtgE’s substrates, Rab29, Rab32, and Rab38, are closely related Rab
GTPases that form their own subclass within the Rab GTPase family [60, 66]. As
illustrated in Figure 4A, Rab29, Rab32, and Rab38 share high homology
throughout much of their primary sequence, but differ in their C-terminal tail,
which is expected because these GTPases have different cellular targets. Rab32
and Rab38 have been implicated in the biogenesis of lysosome-related
organelles (i.e. melanosomes, specialized granules in platelet and T cells, and
the Salmonella-containing vacuole) and coordinate the delivery of cargo to these
organelles [60, 75-77]. In combination with BLOC-1, -2, -3, Rab32 and Rab38
allow for the delivery of antimicrobial proteins to the SCV, consequently leading
to pathogen death [60, 76, 78]. Through cleavage of Rab32 and Rab38, GtgE is
able to circumvent this particular host cell defense pathway. Rab29 remains
uncharacterized thus far [66]. Rab29 is known to associate with the Golgi
complex as well as with lengthy, dynamic tubules extending from the Golgi body,
and it is has been shown that Rab29 is required for the formation of typhoid toxin
transport intermediates [56].
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CHAPTER 2. MATERIALS AND METHODS
2.1 Protein Expression and Purification
Salmonella typhimurium LT2 GtgE 1-228, GtgE79-214, and all other GtgE
constructs were cloned into a modified pCDF-Duet-1 vector (Novagen) between
the SalI and NotI restriction sites. All GtgE1-228 point mutants were generated by
site-directed mutagenesis. GtgE43-214,Δ74-79 was generated by PCR amplifying
GtgE43-73 and GtgE80-214 and stitching the two pieces together via PCR
amplification. Protein was expressed in E. coli BL21(DE3) cells with 0.75mM
IPTG for 16 hours at 18°C. Selenomethionine-substituted GtgE79-214 was
expressed in E. coli 834 cells in selenomethionine-supplemented minimal media
with 0.75mM IPTG at 18°C for 12 hours. Harvested cells were pelleted,
resuspended in 50mM Tris-HCl, pH 8.0, 300mM NaCl, and 5mM imidazole, and
lysed via high-pressure homogenization. Cleared lysate was run over Ni-NTA
resin (Qiagen) and protein was eluted in 50mM Tris-HCl, pH 8.0, 300mM NaCl,
and 500mM Imidazole. Protein was dialyzed against 25mM Tris-HCl, pH 8.0,
250mM NaCl, and 5mM DTT, and the N-terminal Histidine tag was cleaved off
with 6xHis-rhinovirus 3C protease. The material was passed over Ni-NTA to
remove the histidine tag and 3C protease. The final purification step was size
exclusion chromatography using a Superdex 75, 120mL column (GE Healthcare).
Native and selenomethionine-substituted GtgE79-214 was purified into 25mM
HEPES, pH 8.0, 250mM NaCl, and 5mM DTT. GtgE1-228 constructs were purified
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into 25mM Tris-HCl, pH 8.0, 250mM NaCl, and 5mM DTT. Purified protein was
stable at -80°C for up to 3 months.

Human Rab381-211 was cloned into a modified pCDF-Duet-1 vector
(Novagen) between the SalI and NotI restriction sites. Purification was carried
out identically to the purification of GtgE; however, all Rab381-211 buffers
contained 5mM MgCl2 and final purification was done on a Superdex 200, 120mL
column (GE Healthcare) into 25mM Tris-HCl, pH 8.0, 250mM NaCl, 5mM MgCl2,
5mM DTT. Purified protein was stored at -80°C.

To form the complex of GtgE and Rab29/Rab38, GtgE and its Rab
substrate were co-expressed from a modified pCDF-Duet-1 vector (Novagen).
Rab29 or Rab38 was cloned between the SalI and NotI restriction sites and was
N-terminally histidine-tagged. GtgE was cloned into the tag-free second cloning
site between NdeI and XhoI restriction sites. Protein was expressed in E. coli
BL21(DE3) cells with 0.75mM IPTG for 16 hours at 18°C. The complex was
purified according to the purification conditions used for Rab381-211, and during
the final Superdex 200, 120mL column (GE Healthcare) run, the material was
exchanged into 25mM Tris-HCl, pH 8.0, 250mM NaCl, 5mM DTT, and 100μM
MgCl2. Combinations of different GtgE and Rab29/Rab38 point mutants were
generated by site-directed mutagenesis and were expressed and purified
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according to the protocol described for the wild-type complex. The point mutants
used in this work are detailed in Table 4. Purified protein was stored at -80°C.

2.1.1 Urea Denaturation and Dialysis-based Refolding

Protein was expressed from E. coli BL21(DE3) cells and lysed as
previously described. Lysate was cleared via centrifugation, and the resulting
pellet (insoluble fraction) was resuspended in 6M urea, 0.5M NaCl, and 20mM
Tris-HCl pH 8.0. Resuspended material was centrifuged at 16,000 rpm for 40
minutes, and the supernatant was applied to NiNTA resin (Qiagen) that had been
equilibrated in 6M urea, 0.5M NaCl, and 20mM Tris-HCl pH 8.0. The column was
washed with 6M urea, 0.5M NaCl, 30mM imidazole, and 20mM Tris-HCl pH 8.0.
Protein was eluted with 6M urea, 0.5M NaCl, 500mM imidazole, and 20mM TrisHCl pH 8.0. All work was done at room temperature.

Refolding was performed through four rounds of dialysis at 4°C in 20mM
Tris-HCl pH 8.0, 250mM NaCl, 5% glycerol, 2mM EDTA, and 5mM DTT. The
protein sample was diluted to approximately 0.1 mg/mL, and the protein to
refolding buffer volume ratio did not exceed 1:20. The first three rounds of
dialysis were 2-4 hours in length. For the final round, which was allowed to
dialyze for 16 hours, glycerol and EDTA were removed from the buffer and the
samples were treated with 6xHis-rhinovirus 3C protease to cleave the histidine
tag. Purification then followed the protocol stated above for native proteins.
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2.2 Limited Proteolysis
90μg GtgE43-214 was treated with subtilisin protease (Sigma Aldrich) in a
range of 0.55μg to 10.92μg with 5mM CaCl2 for 20 minutes at 4°C. The reaction
was terminated with the addition of 10mM PMSF and SDS loading buffer. The
digest of the Rab38V44I/GtgEC45A complex was run under the same conditions;
however, 34.8μg of complex material was treated with subtilisin ranging from
0.00174μg to 0.261μg and the reaction allowed to proceed for 30 minutes at 4°C.
Cleavage products from both reactions were separated by 15% SDS-PAGE,
transferred to PVDF membrane (Millipore), and stained with SYPRO® Ruby
protein stain (Sigma Aldrich). Major protein bands were cut from the membrane
and sent to the Columbia University Protein Core Facility (New York, NY) for Nterminal Edman degradation sequencing.

2.3 Crystallization and Structure Determination
Native GtgE79-214 was crystallized in a hanging drop format at a 10mg/mL
drop concentration at 4°C in 0.2M Li2SO4, 1.75M (NH4)2SO4, and 0.1M Tris, pH
7.0. Selenomethionine-substituted GtgE79-214 was crystallized by two rounds of
seeding with native crystals at a 10mg/mL drop concentration at 4°C in 0.2M
Li2SO4, 1.75M (NH4)2SO4, 0.1M Tris, pH 7.0. Crystals were cryo-protected in
0.3M LiSO4, 2.5M (NH4)2SO4, 0.1M Tris, pH 7.0 and flash-frozen in liquid nitrogen
for data collection. X-ray data was collected at Brookhaven National Synchrotron
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Light Source (NSLS) Beamline X29, and processed using HKL2000 [79].
Phasing and initial protein building of the selenomethione-substituted protein was
done in Phenix using AutoSol [80-83]. Automated building produced a model
with 133 residues, and the initial model was used subsequently with ARP/wARP
to build a model with the higher resolution native data [84]. Refinement of this
model was carried out with REFMAC5 [85, 86] and manual model building was
done in COOT [87]. TLS refinement [88, 89] was used in the last stages of
refinement to generate a model spanning residues 80-213 with an R/Rfree of
19.31%/22.97% (Table 2). No electron density was observed for residues 79,
145, 146, 171, 193-199, and 214, so these residues were not modeled into the
final structure. 98% of the residues fall into the most favored region of the
Ramachandran plot with no outliers. Figures were generated using CCP4mg
[90].

2.4 Gel-based Activity Assay

The activity assay was performed using Rab38 and GtgE material purified
as detailed. GtgE and Rab38 were mixed in a 1:4 molar ratio in the presence of
10mM CaCl2 and 10mM MgCl2. End-point assays were performed at 4°C for 30
minutes and time-point assays were sampled at 4°C, as described in Figure 11C.
Reactions were stopped with the addition of SDS running buffer and boiled for 10
minutes before visualization by 15% SDS-PAGE and Coomassie staining. Time
point assays were run in triplicate and quantification of GtgE and Rab38 (cleaved
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and uncleaved) band intensity was performed with ImageJ software [91]. These
intensities were first normalized against the loading control, GtgE intensity.
Then, the normalized Rab38 cleavage product intensities were expressed
relative to the total Rab38 in the reaction, and these cleavage product percent
values were summed to convey the product formation in terms of the total Rab38
in the reaction.

2.5 Inhibition Assay

N-ethylmaleimide, antipain, and chymostatin were solubilized in ethanol,
water and DMSO, respectively. 5.75μM GtgE-WT was incubated at room
temperature for 15 minutes with 10mM MgCl2, 10mM CaCl2, and one of the
following additives: water (positive control), 2.5% ethanol/25% DMSO (delivery
controls), or an inhibitor (0.25 mM N-ethylmaleimide (Sigma Aldrich), 5mM
antipain (Sigma Aldrich), and 2.5mM chymostatin (Santa Cruz Biotechnology)).
5.75μM GtgE-C45A was also incubated at room temperature with water as a
negative control. For the leupeptin assay, leupeptin (Sigma Aldrich) was
reconstituted in water and used in the following concentrations: 10μM, 50μM,
100μM, 500μM, 1mM, 2mM, and 5mM. 25.3μM Rab38 was then added and the
reaction was allowed to proceed on ice for 30 minutes. The reaction was ended
by the addition of SDS running buffer and boiling. Results were visualized via
15% SDS-PAGE and Coomassie staining.
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CHAPTER 3. RESULTS AND DISCUSSION
3.1 Domain Determination

Since GtgE lacks significant sequence similarity to proteins of known
structure, the structural determination of GtgE was necessary in order to gain a
conclusive understanding of the enzyme’s active site. Our initial crystallization
attempts focused on full-length GtgE; however, the full-length construct was not
amenable to crystallization, so further construct refinement was done based on
secondary structure predictions and limited proteolysis using subtilisin. A
summary of the constructs tested for crystallization can be found in Table 1.
Constructs with C-terminal truncations past residue 205 were insoluble, and were
purified under denaturing conditions and refolded using a dialysis-based refolding
technique (described in Materials and Methods). Solubility was not affected by
the N-terminal truncations produced in this work; however, it was noted that GtgE
lost activity once the N-terminal 28 residues had been removed (Fig. 5).
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Rab29
alone

GtgE
H151A

GtgE
(1-228)

GtgE
(18-228)

GtgE!
(29-228)!

25kD!
20kD!

10kD!

Figure 5. The effect of N-terminal truncations on GtgE activity. Rab291-177
is cleaved by full-length GtgE as well as by GtgE18-228, but is not cleaved by
GtgE29-228. Rab291-177 that has not been treated with GtgE is in the lane to the far
left. The catalytically dead mutant of GtgE, GtgEH151A, is unable to cleave the
Rab substrate.
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Table 1. GtgE crystallization constructs. Yield is given in milligrams of
protein obtained per liter of cell culture grown.

!

Residue!

pI!

Soluble!

Yield !
(mg/L)!

Active!

1-228!

4.50!

Y!

5.3!

Y!

18-228!

4.31!

Y!

73.4!

Y!

29-228!

4.12!

Y!

15.6!

N!

35-228!

4.12!

Y!

14.8!

39-228!

4.17!

Y!

12.0!

43-228!

4.17!

Y!

15.0!

18-226!

4.31!

Y!

7.7!

18-220!

4.29!

Y!

65.7!

Y!

18-209!

4.19!

Y!

18.6!

N!

18-195!

4.25!

N!

0.9!

18-180!

4.26!

N!

0.9!

18-175!

4.30!

N!

1.7!

18-170!

4.30!

N!

0.9!

29-195!

4.03!

N!

5.2!

39-200!

4.08!

Y!

1.0!

35-209!

4.00!

Y!

6.3!

43-214!

4.08!

Y!

13.1!

43-209!

4.04!

Y!

3.0!

43-200!

4.08!

Y!

1.4!

79-209!

4.05!

Y!

1.6!

79-214!

4.11!

Y!

9.1!

26!

N!

Several rounds of limited proteolysis using subtilisin were performed as
detailed until a minimal, crystallizable construct was determined. Subtilisin
digestion of GtgE43-228 led to the design of a minimal construct of approximately
17kD, spanning residues 79-214, which successfully crystallized (Fig. 6). A 15kD
construct, roughly residues 79-200, was also identified; however, since GtgE is
insoluble with C-terminal truncations past residue 205, this construct was not
pursued. Edman sequencing of the bands showed that both products began at
residue 79, and the C-terminal truncations were predicted based on the products’
molecular weight.

25kD"

GtgE" 0.55μg"
(43-214)"

Subtilisin"

10.92μg"

20kD"
15kD"

79-214"
79-200"

10kD"

Figure 6. Subtilisin digestion of GtgE43-214. Subtilisin concentration shown
increasing from 0.55μg to 10.92μg from left to right. Undigested GtgE43-214 is
shown in the lane at the far left. The digestion produced two cleavage products:
GtgE79-214 and GtgE79-200. The crystallized construct is shown in red.
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3.2 Crystallization and Data Collection
GtgE79-214 was expressed and purified as described. When purified in
25mM Tris-HCl, pH 8.0, 250mM NaCl, and 5mM DTT, and at concentrations
above 30mg/mL, GtgE79-214 exists in both a monomeric and dimeric state.
Purification conditions that yielded stable, monomeric GtgE79-214 were determined
(25mM HEPES, pH 8.0, 250mM NaCl, 5mM DTT; 20mg/mL) and used for the
purification of the crystallized protein product (Fig. 7A).

Ideal crystallization conditions were identified in a 96-well screen using a
sitting drop format, and crystallization was scaled up into a 15-well hanging drop
format to obtain well-diffracting crystals for structural determination. Drops
contained a 1:1 ratio of reservoir buffer to protein, which was at a 20mg/mL
concentration. Crystals grew at 4°C in 0.2M Li2SO4, 1.75M (NH4)2SO4, and 0.1M
Tris pH 7.0, appearing after 3 days and reaching full size in 1-2 weeks (Fig. 7B).
The resulting crystals had a bi-pyramidal morphology and were mildly
birefringent. Crystals were cryoprotected with 0.3M LiSO4, 2.5M (NH4)2SO4,
0.1M Tris, pH 7.0 and frozen in liquid nitrogen for diffraction data collection.
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A!

76.39mL!

B

C

Native!

SeMet: Seeding with native crystals!

20kD!
15kD!

Figure 7. The purification and crystallization of GtgE79-214. (A) Purification of
GtgE79-214 on a Superdex75, 120mL column. The construct behaves as a
monomer under the detailed conditions, eluting at 76.39mL. Lane 1 (far left)
contains the molecular weight marker, lane 2 is the column load material, and the
remaining lanes are the fractions corresponding to the elution peak. (B) Crystals
of native GtgE79-214 grown at 4°C in 0.2M Li2SO4, 1.75M (NH4)2SO4, 0.1M Tris pH
7.0 with an initial set-up protein concentration of 20mg/mL. (C) Crystals of
selenomethionine-substituted GtgE79-214 were grown under the same conditions
used for native crystal growth.
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GtgE’s amino acid sequence does exhibit significant homology to any
proteins of known structure; therefore, phase determination was carried out
experimentally via single-wavelength anomalous diffraction (SAD) using
selenomethionine. Selenomethionine contains selenium, a heavy atom, in place
of the sulfur normally present in methionine, and can usually be incorporated into
a given protein with very little effect on the overall protein structure. Heavy
atoms, such as selenium, are able to absorb X-rays and reemit the absorbed
radiation with an altered phase, producing a measurable difference in intensity
between two Friedel pair reflections. This scattering effect, known as anomalous
scattering, is most prominent when the X-ray wavelength is near the absorption
edge of the heavy atom, which for selenium is 0.980Å. SAD enables the location
of heavy atoms, and when combined with density modification, allows for the
determination of phases for the entire structure.

For measurable anomalous scattering and subsequent successful phase
determination, roughly 1 selenium atom per 100 amino acids is required in the
crystallized protein [92, 93]. GtgE79-214 is 135 residues in length and contains
three methionines, which equates to 1 selenium atom for every 45 residues,
making GtgE an ideal candidate for phase determination with selenium as the
anomalous scatterer. Selenomethionine-substituted GtgE79-214 was produced as
detailed. Crystals of selenomethionine-substituted GtgE79-214 were grown under
the same conditions as the native crystals through successive rounds of seeding,
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starting with native crystals. These crystals had the same morphology as the
native crystals, but were smaller in size, only growing to roughly two-thirds the
size of the native crystals (Fig. 7C). The selenomethionine-substituted crystals
were cryoprotected using the same cryoprotectant as was used for the native
crystals and were also flash frozen in liquid nitrogen prior to data collection.

1.85Å!

2.35Å!

Figure 8. Diffraction pattern from native GtgE79-214 crystals. Diffraction data
was collected at NSLS Beamline X29. Native crystals diffracted to 1.65Å and
selenomethionine-substituted crystals diffracted to 2.38Å.
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Table 2. Crystallographic Statistics for GtgE80-213.

Selenomethionine-substituted!

Native!
Data Collection!
Space group
Cell Dimensions!
a, b, c (Å)
α, β, γ (°)!
!
Wavelength (Å)
!
Resolution (Å)
!
No. of reflections
No. of unique reflections
R-merge† !
!
Mean I/σ(I)
Completeness (%)
Redundancy !
!

!

!P41 21 2

!
!
!
!
!
!
!
!
!
!

!56.181, 56.181, 125.124
!90, 90, 90 !
!
!1.0750
!
!
!50.00 - 1.65 (1.71 - 1.65)
!420901
!
!
!23155 (2428)!
!
!0.072 (0.894)!
!
!30.13 (3.2)
!92.6 (100.0) !
!
!11.2 (11.7) !
!

Refinement!
Resolution (Å)
!
!
No. of reflections !
!
R-factor‡
R-free‡
Number of atoms
!
macromolecules
!
ligands
!
water
!
Amino acid residues
RMS bonds (Å)
!
RMS angles (°)
Average B-factor
!
Ramachandran favored (%)
Ramachandran outliers (%)

!

!

!

!

!P41 21 2!

!
!
!
!
!
!
!

!
!
!
!
!
!
!
!
!
!

!56.126, 56.126, 125.033!
!90, 90, 90!
!0.9790!
!50.00 – 2.38 (2.47 – 2.38)!
!425153
!!
!15090 (1550)!
!0.162 (0.705)!
!16.45 (4.67)!
!99.0 (100.0)!
!15.3 (15.5)!

!
!

!19.63 - 1.65 (1.693 - 1.65)!
!21891 (1778)!
!0.1931 (0.258)!
!0.2297 (0.250)!
1129!
957!
5!
167!
!124!
0.017!
1.75!
30.40!
98!
0!

Statistics for the highest-resolution shell are shown in parentheses.!
R-free value test set size: 5%!
† As defined and calculated by HKL2000!
‡ As defined and calculated by Refmac5!
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3.3 Overall Structure

The structure of GtgE, residues 80-213, was solved to 1.65Å. Diffraction
data were collected at Beamline X29 at the National Synchrotron Light Source
(NSLS) at Brookhaven National Laboratory (BNL) from selenomethioninesubstituted and native protein crystals (Fig. 8). Both native and
selenomethionine crystals belonged to the P41212 space group, diffracting to
2.38Å and 1.65Å, respectively. The model was built automatically into the SAD
data with Phenix AutoSol [80, 81], and the initial model was used subsequently
with ARP/wARP [84] to build a model with the native data (Table 2).

The final structure of GtgE80-213 is comprised of a six-stranded beta-sheet
that is sandwiched between three helices on one side of the sheet and one helix
on the other (Fig. 9). The beta strands are arranged in an antiparallel beta-sheet
adopting the topology depicted in Figure 9B. There are three beta hairpins
connecting beta strand 2 (β2) to β3, β3 to β4, and β4 to β5, and a beta-turn
located between helix 4 and β6. The structure contains 167 water molecules and
124 amino acids, spanning residues 80-213, with an R/Rfree = 0.1931/0.2297
(Table 2). No electron density was observed for residues 79, 145, 146, 171, 193199, and 214, so these residues were not modeled into the final structure.
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Figure 9. The structure of GtgE80-213. (A) The overall fold of GtgE, residues
80-213. Helices shown in red, beta strands shown in blue, and areas without
observable electron density represented with a dashed line. His151 and Asp169
are depicted as sticks in green. (B) Topology diagram of GtgE, residues 80-213.
Generated by PDBSum [94]. (C) The secondary structure sequence alignment
for GtgE, residues 80-213. There are five helices, numbered and shown in red;
six beta strands depicted in blue and labeled by their sheets; and active residues,
His 151 and Asp169, are indicated with a red box. β-turns are represented by β,
beta hairpins by

!

. Originally generated in PDBSum [94].
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!

205!
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120!
A!

130!

125!

135!

H4!

SECLHAECIVGYDSEVKKVLIYDS NTSPEWQSNIDVYDKLTLAFN!
150!

A!

100!

210!
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170!
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3.3.1 Structural Homologs

Structural homologs were identified using the DaliLite v. 3 [95]. Z-scores
above 2.0 are considered significant, usually corresponding to the presence of
similar folds [96]. There were 740 hits, largely cysteine proteases, with z-scores
above 2.0, and of those hits, 23 had a Z-score above 5.0. The top 20 structure
hits are summarized in Table 3. Our structure reveals significant similarity to
cysteine proteases of Clan CA, namely families C1, C2, and C39 [95]. Clans
denote evidence of a common ancestry, thus proteins within a clan share a
common structural fold. Clan CA proteases share a papain-like catalytic fold
comprised of 6 beta strands sandwiched between a variable number of alpha
helices, and function using a catalytic triad. Two key active residues are a
cysteine positioned at the beginning of an alpha helix and a histidine located at
the beginning of beta strand 3. The third triad member (Asn/Glu for C1; Asn for
C2; Asp/Glu for C39) is located at the end of beta strand 4, and is responsible for
the proper orientation of the catalytic histidine [97, 98]. The catalytic core also
contains a glutamine residue that resides a short distance N-terminal to the
active cysteine, aiding in the stabilization of the reaction intermediate [97].

Proteins are further categorized into families based on their function
and/or catalytic residue organization. In eukaryotes, members of the C1 family
primarily serve as proteolytic enzymes in the lysosomal pathway [98]. C2 family
members include the calcium-dependent calpains, which function in a variety of
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cellular processes, such as signal transduction, apoptosis, and cytoskeletal
remodeling [98]. The C39 endopeptidases are bacterial proteins that are
responsible for the maturation of bacteriocin, a secreted bacterial antibiotic
protein that inhibits the growth of other bacterial species [99].
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Table 3. Structural homologs of GtgE80-213. Homologs identified by the
DaliLite v. 3 Homology Server [95]. Z-scores above 2.0 are considered
significant. There were 740 structure hits with a Z-score of 2.0 or higher.
PDB ID!

!

ZRMSD!
No. of
Length of Sequence
Score!
Residues! Alignment! Identity
(%)!

Description!

3zua-A!

6.3!

2.5!

142!

83!

12!

Alpha-hemolysin
translocation!
ATP-binding protein!

1df0-A!

6.1!

3.3!

624!

85!

14!

M-Calpain!

1u5i-A!

6.0!

3.2!

625!

85!

14!

Calpain 2, large subunit
precursor!

3b79-A!

5.9!

2.4!

125!

77!

8!

Toxin secretion ATPbinding protein!

3k8u-A!

5.5!

2.7!

137!

81!

10!

Putative ABC transporter, !
ATP-binding protein!

4d8e-A!

5.4!

3.7!

254!

89!

15!

Streptopain!

2bu3-B!

5.3!

3.9!

204!

97!

15!

ALR0975 protein!

1mdw-A!

5.3!

3.2!

319!

82!

15!

Calpain II, catyalytic
subunit!

1pvj-C!

5.3!

3.2!

339!

88!

15!

Pyrogenic exotoxin B!

1pvj-B!

5.3!

3.2!

339!

88!

15!

Pyrogenic exotoxin B!

1pvj-D!

5.3!

3.2!

339!

88!

15!

Pyrogenic exotoxin B!

2bu3-A!

5.2!

3.9!

200!

96!

16!

ALR0975 protein!

1cv8-A!

5.2!

3.3!

173!

84!

11!

Staphopain!

3bba-A!

5.2!

3.3!

246!

88!

15!

Interpain A!

2uzj-B!

5.2!

3.6!

249!

88!

15!

Streptopain!

3bba-B!

5.1!

3.3!

250!

88!

15!

Interpain A!

2uzj-B!

5.1!

3.8!

247!

89!

15!

Streptopain!

2ftd-A!

5.1!

3.4!

215!

80!

16!

Cathepsin K!

2nga-B!

5.0!

3.5!

318!

84!

14!

Calpain 8!

2btw-B!

5.0!

3.9!

210!

95!

16!

ALR0975 protein!
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3.4 Identification of the Catalytic Triad

GtgE’s overall fold and placement of its active histidine (His151) align best
to homologs of the cysteine protease superfamily Clan CA (Fig. 10). His151 was
identified as an active residue by Spanò, et al. and confirmed through
mutagenesis, His151Ala, and homolog structural alignment in this work (Fig. 10,
Fig. 11A).

Figure 10. The active site alignment of GtgE80-213 with its structural
homologs. GtgE80-213 (purple) with active residues His151 and Asp169; C39
family member, ComA (PDB: 3K8U, blue) with active residues Cys17, His96,
Asp112 shown; C2 family member Calpain II (PDB: 1MDW, red) with active
residues Cys105Ser, His262, Asn286; and C1 family member papain (PDB:
9PAP, yellow) with active residues Cys(OCS)25, His159, and Asn175.
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3.4.1 Active Cysteine

Our crystal structure did not contain a cysteine in the canonical position,
nor did it contain any cysteines in proximity to the other active site residues. In
addition, the cysteine containing helix present in members of this superfamily
was not present in the active site. Since the crystal structure lacks the first 78
residues of GtgE, we hypothesized that the active site cysteine must be located
in the missing N-terminal domain. To confirm this hypothesis, we made point
mutations (Cys to Ala) of each of the eight cysteine residues in GtgE and tested
the enzyme’s ability to cleave Rab38. Cys45 was the only Cys-to-Ala mutation
that resulted in a loss of activity, and therefore, is the active cysteine of GtgE’s
catalytic triad (Fig. 11B). Although Cys45 is missing from our structure, we
predict, based on the conserved homolog structure, that it resides at the
beginning of a helix formed by the N-terminal residues not included in the
crystallized construct.

3.4.2 Active Aspartic Acid
Based on our structure of GtgE80-213 we were able to narrow down the
possible identity of the third triad member to two residues: aspartic acid 169 and
asparagine 172. Both residues are situated near the end of beta strand 4;
however, no electron density was observed for the side chain of Asn172, so it
could not be determined, from the structure alone, which residue was correctly
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placed to participate in the active site. Through point mutation, Asp169Ala and
Asn172Ala, Asp169 was identified as the third triad member, capable of
significantly decreasing GtgE’s activity; whereas, Asn172Ala does not appear to
have any effect on enzyme activity (Fig. 11A).
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Figure 11. The catalytic triad of GtgE. (A) Mutations (C45A, H151A, D169A)
to the catalytic triad of GtgE greatly reduce enzyme activity in vitro. N172A did
not noticeably affect activity. (B) The Cys-to-Ala mutation activity profile for
GtgE. Of all eight cysteines, only C45A shows a loss of function, indicating that it
is the active cysteine of GtgE. (C) Catalytic triad residues (Cys45, His151, and
Asp169) were mutated to alanines and their cleavage of Rab38 was charted as
percent of total Rab38 cleaved over time, in minutes. Standard error of the mean
indicated with black bars for each time point.
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3.4.3 Quantitative Analysis of Catalytic Triad Mutations

To further investigate the effects of alanine mutations to the catalytic triad
members, GtgE’s cleavage of Rab38 was plotted in terms of the percent of total
Rab38 cleaved over time (Fig. 11C). Under the reaction conditions described,
wild-type GtgE cleaved 36% of Rab38 over the course of 30 minutes with the
reaction reaching completion after 10 minutes of activity. Alanine mutations to
Cys45, His151, and Asp169 resulted in the reduction of GtgE activity by 94%,
89%, and 72%, respectively, indicating that these residues are key components
of GtgE’s active site.

3.4.4 Proposed Catalytic Mechanism

Through this work, we have determined that GtgE is a cysteine
endopeptidase, functioning with a catalytic triad composed of Cys45, His151, and
Asp169. Together, these residues are capable of breaking the peptide bond
between two highly conserved glycine and valine residues located in the Switch I
region of Rab29, Rab32, and Rab38. A proposed mechanism for this reaction is
diagramed in Figure 12.

The reaction is initiated once the Rab substrate enters the active site,
creating an environment in which the nitrogen (ND1) of His151 depronates the
thiol of Cys45. This depronation leads to the nucleophilic attack of the Cys45
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sulfur on the carbonyl carbon of the glycine. A thioester linkage between the
sulfur and the N-terminal section of the Rab substrate is then formed, and the
nitrogen of the valine depronates the pronated His151 nitrogen (ND1), releasing
the C-terminal Rab cleavage product and returning His151 to its initial state. A
water molecule hydrolyzes the thioester linkage, which liberates the N-terminal
Rab cleavage product and regenerates Cys45. Asp169 is not directly involved in
the proton transfer necessary for catalysis; however, it is required for the proper
positioning of His151.
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Figure 12. The proposed reaction mechanism for GtgE. GtgE functions as a
cysteine protease to cleave its Rab substrate (Rab29, Rab32, and Rab38)
between a critical glycine and valine in the Switch I region of these GTPases.
GtgE uses a catalytic triad of Cys45, His151, and Asp169 to perform this
cleavage reaction.
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3.4.5 Complete Active Site Construct Design

Since our crystallized construct does not contain the active cysteine, we
sought to crystallize a larger construct that would encompass the entire active
site. Previous crystallization screens on larger domains of GtgE proved
unsuccessful; therefore, we engineered GtgE43-214, the largest minimal domain
containing all three active residues, based on information obtained from our
structure of GtgE80-213 and its structural homologs.

H2!

H1/H3!

GtgE!

H1!

ComA!

Figure 13. The alignment of GtgE80-213 with ComA, a C39 family member.
ComA (PBD: 3K8U, cyan) and GtgE80-213 (purple) with helices labeled (H1, H2,
etc.) for each and color-coded accordingly. Active residues for both structures
are illustrated in green.
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There were two disordered loops in the GtgE80-213 structure, so to create a
construct with a higher crystallization potential, we mutated residues in each loop
to decrease the surface entropy of the protein and encourage protein-protein
interactions. In disordered loop 1, spanning residues 145 to 147, Leu145,
Ser147, and Glu148 were mutated to alanine. For disordered loop 2, which
spans residues 193 to 199, Lys194, Lys196, and Glu198 were mutated to
alanine. GtgE43-214 constructs with mutations to loop 1 or loop 2 were screened
for crystallization separately as well as together, in a GtgE43-214 construct that
contained mutations in both loop 1 and loop 2.

Through comparison and modeling work between GtgE80-213 and its C39
family structural homologs, it was evident that GtgE contains a larger loop region
located directly N-terminal to the start of GtgE80-213. In the homologs, this loop
connects an alpha helix to the helix corresponding to residues 83-93 (H1) in
GtgE80-213 (Fig. 13). We believe GtgE has a six-residue insertion in this loop,
roughly equivalent to residues 74-79. As further evidence that this region is
loopy and surface exposed, subtilisin digests of GtgE43-214 led to cleavage
immediately N-terminal to residue 79 (Fig. 6). A GtgE construct was designed
with a deletion of residues 74 to 79, and this was tested for crystallization both
alone and in combination with the loop 1 and loop 2 mutations. These
crystallization screens did not yield crystals.
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3.5 GtgE Inhibition

The inhibition of GtgE may serve as a means to alter the host specificity of
broad-host Salmonellae. Equipped with an understanding of GtgE’s function at
the mechanistic level, we were able to identify three small molecules from a
panel of cysteine protease inhibitors that are capable of inhibiting GtgE function
in vitro: N-ethylmaleimide, antipain, and chymostatin (Fig. 14A-C). Nethylmaleimide (NEM) covalently modifies cysteine residues, making it the least
specific, although most potent, of the three inhibitors, showing inhibition at a 1:43
molar ratio of GtgE to NEM (Fig. 14B).

Antipain and chymostatin are both microbial-derived small peptide
inhibitors which contain a C-terminal aldehyde that inhibits cysteine proteases by
forming a hemiacetal adduct with the active thiol [100]. Antipain is bulky in
structure (Arg-Val-Arg-Phe), and broadly targets cysteine and serine proteases
(Fig. 14A). Chymostatin is composed of two phenylalanines, capreomycidine, a
large residue unique to microbes, and a variable hydrophobic residue (Fig. 14A).
Exhibiting greater specificity than antipain, chymostatin inhibits papain,
chymotrypsin, and cathepsins A/B/C/H/L. Chymostatin was two-fold more potent
of an inhibitor for GtgE than was antipain, inhibiting GtgE at a molar ratio of 1:435
GtgE to chymostatin, compared to a molar ratio of 1:870 GtgE to antipain (Fig.
14B). Conversely, leupeptin, another microbial-derived inhibitor comprised of
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residues with relatively small side chains (Leu-Leu-Arg) (Fig. 14A), does not
inhibit GtgE at the highest tested molar ratio (1:870 GtgE to leupeptin) (Fig. 14C).
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Figure 14. Inhibition of GtgE. (A) The structures of cysteine protease
microbial-derived small peptide inhibitors. (B) GtgE is inhibited by NEM,
chymostatin, and antipain. The reactions with chymostatin and its delivery
control, DMSO, were performed separately using identical conditions to that of
the reactions with NEM and antipain; thus, this is indicated with a black line.
(C) Leupeptin does not inhibit GtgE at the highest concentration that could be
tested given leupeptin’s solubility. At a molar ratio of 1:870, GtgE to leupeptin,
leupeptin did not inhibit GtgE’s ability to cleave Rab38. The activity of GtgEC45A is shown as a control.
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The GtgE cleavage site on its Rab29/32/38 substrates is highly conserved
among these three Rab GTPases, consisting predominantly of hydrophobic
residues and several residues with bulkier side chains, such as aspartic acid and
phenylalanine. We theorize that chymostatin and antipain are more suited to
inhibit GtgE because they both contain aromatic residues, whereas leupeptin
does not. Therefore, these inhibitors are better able to mimic the Rab29/32/38
cleavage site, and are best suited to provide the foundation for more targeted
inhibitor design.

3.6 The GtgE/Rab GTPase Complex

To investigate the nature of GtgE’s interaction with its Rab GTPase
substrates, we determined the necessary conditions for stable complex formation
in vitro for the purposes of crystallization and structure determination. We initially
examined complex formation, as verified by an elution peak shift on the size
exclusion Superdex 200, 120mL column (GE Healthcare), between the
catalytically inactive GtgEC45A and Rab29, 32, and 38. Complex stability is
defined here as the ability of the complex to remain in solution at 4°C for at least
several days post-purification, and for the appearance of lower molecular weight
Rab cleavage bands to be minimal.

Rab29 was found to be the least stable in vitro; however, it was found that
Rab29 could be expressed in larger quantities when expressed with a C-terminal
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truncation of the last 26 residues, thereby making it possible to perform
subsequent binding assays using this substrate. Rab38 was determined to be
the most ideal of the three candidates in forming a stable complex with GtgEC45A.
Unlike Rab29 and Rab32, Rab38 did not precipitate during purification and was
even stable for up to 18 hours at room temperature. A cleavage band at
approximately 14kD did appear, as it did during the purification of the other Rabs,
and could be due to cleavage by a contaminating protease or by residual activity
of GtgEC45A itself. The addition of a protease inhibitor cocktail did not prevent this
cleavage.

Various mutations in both GtgE and Rab29/Rab38 were screened in an
effort to identify a combination of mutations that would result in a stable complex
with minimal residual Rab38 cleavage. These mutations, their ability to form a
complex, and the long-term stability of the complex are summarized in Table 4.
The GtgE mutations were initially tested in complex with Rab291-177, and the
Rab29 and Rab38 mutations were complexed with GtgEC45A.
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Table 4. Identifying complex stabilizing mutations in GtgE and Rab29/38.
Mutation!

Complex
Formation!

Long-term!
Stability!

GtgE(C45A)!

Y!

Y!

GtgE(C45A/C48A)!

Y!

N!

GtgE(H151A)!

N!

N!

GtgE(C45A/H151A)!

Y!

N!

Rab29(V40L)!

Y!

N!

Rab29(G41A)!

N!

N!

Rab29(G41V)!

N!

N!

Rab29(G41S)!

N!

N!

Rab38(V44I)!

Y!

Y!

Rab38(V44L)!

Y!

N!

Rab38(F46Y)!

Y!

N!

Rab38(Q69L)!

Y!

Y!

Rab38(S35N)!

Y!

Y!

Mutations in GtgE’s catalytic core were focused on C45A, H151A, double
mutant C45A and H151A, and double mutant C45A and C48A. Of these four,
only the single C45A mutation yielded a stable complex over time. GtgEC45A/C48A formed a complex with Rab291-177, but a significant cleavage band
appeared during purification. The double catalytic mutant C45A/H151A also
formed a complex with Rab291-177, but this complex dissociated during
purification, possibly because the double mutation disturbed the active site in
such a way as to decrease GtgE’s ability to tightly grasp its Rab substrate.
GtgEH151A did not form a complex with Rab291-177.
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To examine GtgE’s ability to recognize Rab38 in its GTP-bound (“on”)
state or its GDP-bound (“off”) state, constitutively active (Q69L) and constitutively
inactive (S35N) mutations on Rab38 were produced. The constitutively active
glutamine to leucine mutation prevents the binding of the GTPase Activating
Protein (GAP) so that there is no external stimulation of the Rab’s GTPase
activity [101]. The glutamine residue also plays an important role in GTP
hydrolysis, forming a hydrogen bond with a water molecule positioned to attack
the phosphoryl bond of GTP [102]. Since leucine cannot participate in such an
interaction, the Q69L mutation also inhibits the Rab’s intrinsic rate of GTP
hydrolysis [101, 103].

The constitutively inactive mutant, serine to asparagine, increases the
Rab’s affinity for GDP [104]. The inactive mutant retains its ability to bind
Guanine Nucleotide Exchange Factors (GEFs), but since exchange for GTP does
not occur, the mutant Rab forms a dead-end complex with its GEF, and
therefore, is trapped in its ‘off’ state [105]. GtgEC45A binds both Rab38Q69L and
Rab38S35N with equal affinity, as judged by the ratio of GtgE to mutant and wildtype Rab38 purified in complex by size exclusion chromatography. Therefore,
based on this work, GtgE does not show preference for either Rab conformation,
and is able to recognize and bind stably to both the constitutively active and
constitutively inactive Rab38 mutants.
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We also made various mutations around the GtgE cleavage site on Rab29
and Rab38 to identify a mutation that led to a decrease in the appearance of
lower molecular weight Rab products. Mutations in Gly41 in Rab29 prevented
complex formation with GtgEC45A, and only one mutation in Rab38, V44I, made a
significant reduction in the formation of the 14kD cleavage band.

The purification of the GtgEC45A/Rab38V44I complex on the Superdex 200,
120mL column (GE Healthcare) is shown in Figure 15A. GtgEC45A elutes at
89.23mL (Fig. 15B), Rab38V44I elutes at 93.52mL (Fig. 15C), and the complex
elutes at 88.44mL (Fig. 15A). Through work with the wild-type complex
(Rab38/GtgEC45A), it was determined that the complex is most stable at a
relatively neutral pH (pH 7.5-8.0), a salt concentration of 100mM-250mM sodium
chloride, 5mM of reducing agent dithiothreitol, and a minimum of 100μM
magnesium chloride. The Rab GTPases are not stable without the addition of
magnesium chloride, as the magnesium ion is necessary for the protein’s stable
interaction with GTP/GDP. Complex preparations were performed with an
excess of magnesium chloride, 5mM MgCl2, and material used for crystallization
was exchanged into buffer containing 100μM MgCl2. Additionally, complex
formation was affected by the method of expression used for the two
components. A stable complex was only obtained when Rab38 and GtgEC45A
were co-expressed on the same plasmid with Rab38 N-terminally His-tagged and
GtgEC45A untagged.
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Figure 15. The purification of full-length Rab38V44I and full-length GtgEC45A.
(A) GtgEC45A and Rab38V44I, in complex, elutes at 88.44mL on a Superdex200,
120mL column (GE Healthcare). (B) GtgEC45A elutes at 89.23mL. (C) Rab38V44I
elutes at 93.52mL. Lane 1 (far left) on gels is the molecular weight marker, lane
2 is the column load material, and the remaining lanes are fractions
corresponding to the elution peak.

Crystallization screens were carried out with each stable variation of the
complex that was produced. The Rab38V44I/GtgEC45A material was subjected to
limited proteolysis by subtilisin and trypsin to identify minimal constructs for
crystallization. The subtilisin digest is shown in Figure 16. The complex was
treated with subtilisin, ranging from 1.7ng to 0.261μg, and the reaction was
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incubated for 30 minutes at 4°C. There were two main cleavage products at
approximately 23kD and 19kD. Edman sequencing of these bands revealed that
the 23kD product corresponds to full-length Rab38V44I and GtgE18-228, C45A, and
the 19kD band corresponds to GtgE57-228, C45A. A robust co-expression of Rab38
V44I

with GtgE18-228, C45A was not possible, yielding low expression levels of mostly

insoluble GtgE18-228, C45A. However, a complex between Rab38 and GtgE23-228,
C45A

was successfully purified, but was unsuccessful in crystallization screens.

Rab38V44I!
GtgEC45A!
1.7ng!

Subtilisin!

25kD!
20kD!

0.261μg!

Rab381-211/GtgE18-228!
GtgE57-228!

15kD!

Figure 16. Limited proteolysis of the Rab38V44I /GtgEC45A complex. The
complex was digested with 1.7ng to 0.261μg of subtilisin protease. The reaction
was performed at 4°C for 30 minutes. Untreated complex material is shown in
the far left lane.

!

55!

CHAPTER 4. CONCLUSIONS
Members of the cysteine protease superfamily participate in a diverse
array of biological pathways. The conserved active site triad is remarkably
adaptable to seemingly disparate chemical reactions, functioning within enzymes
as different as proteases, acetyltransferases, transglutamases, deamidases, and
deubiqutinases. The catalytic activity of these enzymes is driven by a
nucleophilic cysteine thiol and an electron-accepting histidine, and often requires
a third residue for the proper orientation of this cysteine-histidine pair.
Superfamily members share a conserved overall fold, but differ in the placement
of catalytic triad residues within their canonical active site.

Interestingly, a sizeable portion of characterized bacterial T3SS effector
proteins belong to the cysteine protease superfamily, utilizing this cysteinepowered catalytic core to manipulate the host’s cellular processes in a variety of
ways. For example, Escherichia coli encoded Cif, functions as a deamidase,
using a Cys-His-Gln catalytic core to deamidate a critical glutamine in the
ubiquitin-like NEDD8 protein [106]. Through binding to and deamidating NEDD8,
Cif effectively prevents the E3 ligase activity of neddylated CRL complexes,
resulting in cell cycle arrest, formation of stress fibers, and host apoptosis [107112]. Another cysteine protease effector, Yersinia pestis Yop J, employs its HisGlu-Cys triad to acetylate serine and threonine residues on MAPK kinases and
the IκB kinase complex, inhibiting both MAPK signaling and activation of the
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NFκB pathway, respectively [113, 114]. YopJ’s catalytic activity ultimately leads
to the inhibition of innate and adaptive immunity responses and to the induction
of cell death [113, 115-117]. In addition, S. typhimurium produces a
deubiquitinase, SseL, which functions using a His-Asn-Cys triad to remove K63linked ubiquitin chains from SCV-associated aggregates that are targeted for
autophagic degradation [118, 119]. In this manner, SseL decreases the
autophagic flux within the host, consequently contributing to down modulation of
NF-κB-dependent cytokine production and macrophage-delayed cytotoxicity
[118-121].

GtgE is the newest addition to this growing list of bacterial effector
cysteine proteases. Produced by S. typhimurium, GtgE cleaves its Rab GTPase
substrates, Rab29, Rab32, and Rab38, preventing the delivery of antimicrobial
agents to the SCV; thereby, subverting one facet of the host’s defense
mechanism. In this manner, GtgE contributes to the ability of broad-host strains
of Salmonella to maintain a diverse repertoire of host species. Our crystal
structure of GtgE80-213 firmly establishes that GtgE is a cysteine protease of Clan
CA utilizing a catalytic triad of Cys45, His151, and Asp169. Biochemical studies
with mutations in the active site residues show dramatic loss of activity against
the Rab GTPases.
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The inhibition of GtgE may serve as a means to alter the host specificity of
broad-host Salmonellae. Equipped with an understanding of GtgE’s function at
the mechanistic level, we were able to identify three small molecules from a
panel of cysteine protease inhibitors that are capable of inhibiting GtgE function
in vitro: N-ethylmaleimide, antipain, and chymostatin. All of these compounds
target the active thiol; however, due to their more specific inhibition, antipain and
chymostatin are best suited to provide the foundation for more targeted inhibitor
design. Chymostatin and antipain are bulkier microbial-derived small peptide
inhibitors, which more closely mimic the cleavage site of GtgE’s Rab GTPase
substrates. Conversely, leupeptin, a microbial-derived inhibitor comprised of
residues with relatively small side chains, targets the active thiol in the same
manner as chymostatin and antipain, but does not inhibit GtgE.

Our work with the GtgE/Rab GTPase complex has led to the identification
of in vitro conditions that maintain long-term stability of the complex. Of GtgE’s
substrates, we have shown that Rab38 is the most amenable to in vitro work and
with additional purification optimization, the GtgE/Rab38 complex may prove to
be the best option for crystallization of the complex. Through obtaining a
structure of GtgE in complex with its substrate, we hope to characterize GtgE’s
interaction and possible recognition of its substrate, providing a more thorough
understanding of how GtgE functions in vivo.

!

58!

Since Rab GTPases undergo significant structural changes depending on
whether they are bound to GDP or GTP, it is imperative to crystallization success
that the Rab protein under study adopts a homogenous conformation. We
attempted to address this by making constitutively active, GTP-bound
conformation, and constitutively inactive, GDP-bound conformation, mutations to
Rab38. We did not find a measurable difference in complex formation or stability
between GtgE and the constitutively active or inactive mutant of Rab38, and
neither complex yielded crystals. Another method that may prove more useful in
creating Rab homogeneity is to chemically induce nucleotide loading of either
GDP or a non-hydrolyzable analog of GTP, such as Gpp(NH)p. This method
may better mimic the GDP/GTP-bound conformations of Rab in vitro, perhaps
leading to a more tightly bound, stable complex and potentially aiding in
crystallization.
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APPENDIX I. SALMONELLA INVASION PROTEIN C
AI.1 Introduction

Salmonella Invasion Protein C (SipC/SspC) is encoded on Salmonella
pathogenicity island 1 and is secreted by the T3SS1 [122]. Expression and
secretion of SipC is controlled by its chaperone, Salmonella invasion chaperone
A (SicA) [123, 124]. SipC plays a critical role in Salmonella infection, serving as
both a translocase and an effector protein, and is necessary for host invasion
[125, 126]. SipC is a 42kD protein with one predicted transmembrane domain
and two effector domains (Fig. 17).

SipC!
SipB!

1!
F-actin!
Bundles!

200!

Actin Nucleation!

Actin Bundling!

120!

Host !
Membrane!

F-actin!

409!
G-actin!

Figure 17. SipC and host cell invasion. SipC is a 409 residue effector and
translocase protein, and is predicted to oligomerize with SipB to form the
translocon pore in the host cell membrane. The N-terminal 120 residues of SipC
extend into the host cytosol where they function in actin bundling, while the Cterminal 209 residues nucleate actin polymerization.
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Shigella flexneri invasion plasmid antigen C (IpaC) is highly homologous
to SipC, sharing 34% amino acid identity and 54% similarity with SipC [127].
IpaC and SipC share a significant sequence homology in their respective
hydrophobic domains and C-terminal effector domain, and both are known to
interact with actin [128]. A key difference in the way Shigella and Salmonella
infect cells is that Salmonella remains within the SVC after host entry, while
Shigella escapes into the host cytoplasm [128]. SipC and IpaC appear to be
important players in this difference in infection behavior, although the exact
cause of this difference remains unknown [128].

AI.1.1 The Translocon

SipC oligomerizes with Salmonella Invasion Protein B (SipB), another
translocase protein, to form the translocon pore in the host cell membrane. The
two proteins have been shown to associate in vitro [30], but it is not understood
how they are inserted into, and associate within, the membrane. SipC is not
detected in the host cell membrane in the absence of SipB, suggesting that SipC
is dependent on SipB for membrane insertion [25, 127]. It is unclear whether
SipB and SipC oligomerize into a ring structure prior to membrane insertion, but
complex formation between SipC and SipB is essential for their insertion into the
membrane, and a domain of SipC, residues 340 to 409, is required for its
interaction with SipB [129]. Once inserted into the membrane, SipC is
hypothesized to assume a hairpin-like formation, such that its central
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hydrophobic domain resides within the plasma membrane while its N- and Cterminal effector domains extend into the host cell cytoplasm (Fig. 17) [25].

AI.1.2 SipC: N-terminal Domain

Functioning as a Salmonella effector protein, SipC participates in the
rearrangement of the host’s actin cytoskeleton, aiding in Salmonella’s initial
uptake by the host. Actin rearrangement by SipC appears to be enhanced by the
action of another Salmonella invasion protein, SipA, suggesting that SipC
cooperates with SipA in vivo [130]. Both SipC and SipA appear to bind directly to
actin and influence filament dynamics independently of host cell components
[30]. The N-terminal domain of SipC, spanning residues 1 to 120, bundles actin
filaments in a 1:1 SipC to actin filament molar ratio in vitro [30].

Actin is a 42kD globular protein that serves as the building block for
microfilament formation in eukaryotic cells. There is a large variety of eukaryotic
actin binding proteins that help to tightly regulate microfilament dynamics inside
the cell. Monomeric actin, known as G-actin, polymerizes to form long,
filamentous, double-helical polymers, called F-actin. Proteins responsible for
actin bundling, such as the N-terminal domain of SipC, are able to group together
F-actin strands into bundles (Fig. 17). These bundles function primarily in
maintaining the overall cell structure; allow for force generation; and are also
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important for phagocytosis [131, 132]. Through actin bundling, the N-terminal
domain of SipC stimulates host phagocytosis and uptake of the Salmonella cell.

AI.1.3 SipC: C-terminal Domain

The C-terminal domain of SipC, residues 200 to 409, nucleates actin
polymerization in vitro (Fig. 17) [30]. Since the G-actin concentration inside the
cell is kept below the critical concentration, the concentration above which Gactin polymerizes, the action of actin-nucleating proteins, such as SipC, is
necessary for actin polymerization [33]. Actin polymerization follows three
distinct phases: lag phase, filament growth, and steady state (Fig. 18).
Nucleation begins during the lag phase and continues until approximately 45% of
the actin is polymerized [133]. During filament growth, filaments polymerize from
nucleating centers, and a steady state is achieved once the concentration of
monomeric actin drops to the critical concentration causing polymerization to
cease [133]. Proteins that nucleate actin polymerization increase the number of
nucleating centers; therefore, decreasing the length of the lag phase, enabling
polymerization to begin sooner, and steady state to be achieved faster, than with
actin alone. By nucleating actin polymerization, the C-terminal domain of SipC
enables Salmonella to exploit host actin, ultimately leading to the internalization
of the bacterial cell by the host.
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Figure 18. Actin polymerization. The polymerization of actin occurs in three
stages: lag phase, filament growth, and steady state. When a nucleating protein
is added to monomeric actin, the lag phase is eliminated and filament formation
occurs logarithmically.

SipC has an activity range similar to that of the Arp 2/3 complex, which is
considered to be a relatively weak nucleator in vitro [30, 134]. Thus far, several
studies have investigated the actin polymerization ability of SipC’s C-terminal
domain, and have found that, in order to function in vitro, this domain
multimerizes via contact points located between residues 201 to 220 [135].
Through in-frame deletion/insertion mutations, residues 201 to 220 were also
found to be essential for actin nucleation, while residues 321 to 409 were
required for translocation of effectors [25, 136].
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Two eukaryotic proteins, cytokeratin 8 and Exo70, are believed to interact
with the C-terminal domain of SipC. Yeast two-hybrid experiments with HeLa cell
cDNA identified cytokeratin 8, a 54kD intermediate filament protein, as a potential
binding partner of SipC [25]. Cytokeratin 8 is comprised of three domains: a nonhelical N-terminal domain, an alpha helical rod domain, and a non-helical tail [25].
In this yeast two-hybrid screen, SipC was found to interact with a C-terminal
segment of cytokeratin 8, spanning roughly two-thirds of the second coil in the
rod domain in addition to the entire tail domain [25]. The central alpha helical
domain forms heterodimers with cytokeratin 18 to assemble into dynamic
filaments that are approximately 10nm in diameter and extend from the nucleus
to the plasma membrane [137]. Mutations in the C-terminal effector domain of
SipC disrupted the interaction between SipC and cytokeratin 8, suggesting that
SipC directly interacts with this filament protein and may utilize this interaction to
influence the cytoskeletal structure of the host [25].

A study by Nichols, et al. found that the C-terminal domain of SipC is
sufficient to cause the co-precipitation of endogenous Exocyst Complex
Component 7 (Exo70, EXOC7) from HeLa cell lysate [138]. Exo70 is one of eight
exocyst complex proteins that, together, mediate the docking and fusion of
exocytic vesicles with the plasma membrane. Exo70 is an 84kD protein
composed of three helical domains, termed the N, M, and C domains [139].
Exo70 interacts with several Sec proteins (Sec6, Sec8, Sec10, and Sec15), as

!

65!

well as Arpc1 and numerous small GTPases to target and tether exocytic
vesicles to the plasma membrane in preparation for SNARE-mediated fusion
[139, 140]. Through its interplay with Arpc1, a subunit of the Arp2/3 complex,
Exo70 stabilizes actin reorganization at the plasma membrane [141]. SipC is
capable of binding Exo70 in its unbound state as well as when it is assembled
into the exocyst complex [138]. SipC’s interaction with Exo70 serves as another
means for Salmonella to gain access to the host actin cytoskeleton, enabling the
bacteria to encourage its own internalization through host phagocytosis.

As an effector protein, SipC is able to interact with host actin both directly,
through its N- and C-terminal domains, and indirectly, via its interaction with
cytokeratin 8 and Exo70. Despite this functional characterization, it is difficult to
predict how SipC carries out actin rearrangement because the effector lacks
primary sequence homology to other known eukaryotic actin binding proteins
[130]. Our aim was to provide structural insight into how this key component of
Salmonella invasion performs its various effector roles by obtaining the X-ray
structure of SipC.
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AI.2 Materials and Methods

AI.2.1 Protein Expression and Purification
SipC1-120, SipC1-120(7+), and SipC5-120 were cloned between the SalI and
NotI restriction sites in a modified pGEX4 vector (GE Healthcare), containing a
rhinovirus 3C protease cleavage site C-terminal to GST, and protein was
expressed in E. coli BL21(DE3) cells for 16 hours at 21°C with 1mM IPTG. Cells
were lysed by high-pressure homogenization into lysis buffer (50mM Tris-HCl, pH
8.0, 200mM NaCl, and 10mM DTT). Lysate was centrifuged for 40 minutes at
16,000rpm and supernatant was first passed over a Q-sepharose column (GE
Healthcare) that was pre-equilibrated in lysis buffer. Q-sepharose flow-through
was then run over a glutathione-sepharose column (GE Healthcare) preequilibrated with lysis buffer. The column was washed with 50mM Tris-HCl, pH
8.0, 500mM NaCl, and 10mM DTT, and protein was eluted from the column with
50mM Tris-HCl, pH 8.0, 200mM NaCl, 10mM DTT, and 10mM glutathione.
Eluted protein was dialyzed for 16 hours at 4°C with in-house prepared 6xHisrhinovirus 3C protease into 50mM Tris-HCl, pH 8.0, 150mM NaCl, and 5mM
DTT. After dialysis, the protein was passed over a NiNTA column (Qiagen) to
remove the histidine-tagged 3C protease. In order to separate free GST from
untagged SipC1-120, the material was diluted with 50mM Tris-HCl, pH 8.0, 5mM
DTT to a NaCl concentration of 50mM NaCl, and was then loaded onto a Source
Q column (GE Healthcare) that was pre-equilibrated in 50mM Tris, pH 8.0, 5mM
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DTT. The Source Q column was then washed with 50mM Tris-HCl, pH 8.0, 5mM
DTT and the bound proteins, free GST and SipC1-120, were eluted from the
column separately using a salt gradient of 0-100% NaCl, run over 160 minutes.
Free GST eluted with about 100mM NaCl and SipC1-120 eluted at approximately
300mM NaCl. SipC1-120 was then run over a 120mL Superdex 75 column (GE
Healthcare) into 50mM Tris-HCl, pH 8.0, 150mM NaCl, and 5mM DTT. Peak
fractions were collected and concentrated using a 3kD Amicon Ultra centrifugal
concentrator (Millipore), and loaded onto a 25mL Superdex 200 column (GE
Healthcare) into a final buffer containing 25mM Tris-HCl, pH 8.0, 150mM NaCl,
and 2mM DTT.

SipC1-120 was also cloned into a modified pCDF-Duet-1 vector (Novagen)
between the SalI and NotI restriction sites. Protein was expressed in E. coli
BL21(DE3) cells at 21°C with 1mM IPTG for 16 hours. Cells were lysed with
high-pressure homogenization into 50mM Tris-HCl, pH 8.0, 300mM NaCl, and
lysate was centrifuged at 16,000rpm for 40 minutes. The resulting pellet was
resuspended in 6M urea, 0.5M NaCl, and 20mM Tris-HCl, pH 8.0, and
centrifuged again at 16,000rpm for 40 minutes. The supernatant was applied to
NiNTA resin (Qiagen) that had been equilibrated in the resuspension buffer. The
column was washed with 6M urea, 0.5M NaCl, 30mM imidazole, and 20mM TrisHCl, pH 8.0. Protein was eluted with 6M urea, 0.5M NaCl, 500mM imidazole,
and 20mM Tris-HCl, pH 8.0. Work was carried out at room temperature.
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SipC1-120 was refolded via dialysis refolding at 4°C with protein at 0.2
mg/mL as detailed in section 2.1.1. 6xHis-rhinovirus 3C protease was added
during the final stage of dialysis to remove the histidine tag, and the 3C protease
and cleaved histidine tag were separated from SipC1-120 via a passage over a
NiNTA column, and SipC1-120 was then further purified over a 120mL Superdex 75
column (GE Healthcare) and 25mL Superdex 200 column (GE Healthcare) as
described above.

SipC200-409 and all other SipC C-terminal domain constructs were cloned
into a modified pCDF-Duet-1 vector (Novagen) between the SalI and NotI
restriction sites. Protein was expressed in E. coli BL21(DE3) competent cells
with 1mM IPTG at 21°C for 16 hours. Cells were lysed via high-pressure
homogenization into lysis buffer (50mM HEPES, pH 7.5, 300mM NaCl, and 5mM
imidazole). Lysate was centrifuged for 40 minutes at 4°C and 16,000rpm.
Supernatant was passed over a NiNTA column (Qiagen) pre-equilibrated in lysis
buffer at 4°C. The column was washed with 50mM HEPES, pH 7.5, 300mM
NaCl, 30mM imidazole, and protein was eluted with 50mM HEPES pH 7.5,
300mM NaCl, 250mM imidazole. Eluted protein was dialyzed with 6xHIsrhinovirus 3C protease for 16 hours at 4°C against 25mM HEPES, pH 7.5,
200mM NaCl, and 5mM DTT. The protein was then run over a NiNTA column
(Qiagen) to remove the histidine tag and 3C protease. Final purification was
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done on a 120mL Superdex 75 column (GE Healthcare) into 25mM HEPES, pH
7.5, 200mM NaCl, and 5mM DTT.

M. musculus Exo701-653 and Exo7085-653 (mExo70) (Source Bioscience)
were inserted between the SalI and NotI restriction sites of a modified pCDFDuet-1 vector (Novagen) containing a hisitidine-NusA tag and rhinovirus 3C
protease cleavage site. Purification of mExo70 was performed according to the
purification scheme described for SipC C-terminal domain constructs, except that
buffers were made with 25mM Tris-HCl, pH 8.0 and the final purification step was
done on a 120mL Superdex 200 column (GE Healthcare) in 25mM Tris-HCl, pH
8.0, 200mM NaCl, and 5mM DTT. Both mExo1-653 and mExo85-653 eluted as
monomers under these conditions.

To co-express mExo7085-653 with SipC200-409, SipC200-409 was cloned into
the second cloning site of a modified NusA-containing pCDF-Duet-1 vector
(Novagen) (described above) between the NdeI and XhoI restriction sites.
Purification of the complex was carried out in the same manner as for mExo70
alone, using buffers containing 25mM Tris, pH 8.0. To further probe for complex
stability, the elution from NiNTA resin (Qiagen) was applied to a 120mL Superdex
200 column (GE Healthcare) in 25mM Tris pH, 8.0, 200mM NaCl, and 5mM DTT.

!

70!

S. typhimurium SpvB was purified as described by Margarit, et al. [142].
Briefly, SpvB was histidine-tagged and purified using standard NiNTA procedures
and protein was eluted in buffer containing 50mM Tris-HCl, pH 8.0, 300mM NaCl,
250mM imidazole. The final stage of purification was performed on a 120mL
Superdex 75 column (GE Healthcare) into 10mM Tris-HCl, pH 8.0, 100mM NaCl,
and 2mM DTT.

AI.2.2 Limited Proteolysis
Histidine-tagged SipC200-402 was subjected to limited proteolysis using
subtilisin protease (Sigma Aldrich). 11.5μg of SipC200-409 was incubated with
3.45ng to 11.5ng of subtilisin and 5mM CaCl2 for 30 minutes at 4°C. In a similar
reaction, 8.05μg of SipC200-330 was treated with 48.3ng to 0.483μg of trypsin
(Sigma Aldrich) and 5mM CaCl2 for 30 minutes at room temperature. The
reactions were terminated by the addition of 10mM PMSF and SDS running
buffer. Samples were boiled and run on 15% SDS-PAGE and transferred to
PDVF membrane (Millipore) for Edman sequencing by the Rockefeller University
Proteomics Resource Center (New York, NY).

AI.2.3 Reductive Methylation of Lysine Residues
The lysine residues of SipC200-409, SipC200-295, SipC200-290, and SipC195-278
were reductively methylated using a protocol adapted from Rayment [143]. The
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SipC constructs were used in a concentration range of 0.1-0.5mg/mL in a 2mL
volume and were in a buffer containing 25mM HEPES, pH 7.5, 200mM NaCl, and
5mM DTT. 40mM dimethyl-amine-borane (DMAB, Sigma Aldrich), prepared in
water, and 80mM methanol-free formaldehyde (Polysciences, Inc.), prepared in
water, were added to SipC in a falcon tube. The tube was wrapped in aluminum
foil and allowed to incubate at 4°C for 2 hours with gentle mixing. An additional
40mM DMAB and 80mM formaldehyde were added to the SipC methylation
reaction and the reaction was again incubated, gently mixing, at 4°C for 2 hours.
5mM DMAB was added to the sample, and the reaction was slowly shaken for 16
hours at 4°C. 250mM ammonium sulfate was then added to the sample to end
the methylation reaction. As a final purification step, and to confirm successful
methylation, SipC samples were run over a 120mL Superdex 75 column (GE
Healthcare) into 25mM HEPES, pH 7.5, 200mM NaCl, and 5mM DTT.

AI.2.4 Crystallization
Crystallization screens with SipC200-295 were performed in a 96-well sitting
drop format using approximately 5mg/mL protein in a 1:1 ratio with reservoir
buffer to a total volume of 2μL. Spherulite formation was observed at room
temperature in a wide range of different conditions, though mostly at a relatively
neutral pH. Spherulite hits were globular with a smooth surface.
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The SipC195-278 crystal screen set-up was analogous to that used for SipC200-295,
however, the 2μL sitting drops contained 16mg/mL protein in a 1:1 ratio with
reservoir buffer. Spherulite formation was seen at room temperature and at 4°C
predominantly in conditions containing low molecular weight PEGs (PEG 20005000). Reductively methylated SipC195-278 was also tested for crystallization
under the same screening conditions used for native SipC195-278, and spherulites
with thicker needle-like extensions were obtained in 0.1M sodium acetate pH 4.6,
2M ammonium sulfate.

AI.2.5 SipC and Ribosylated Actin

Rabbit skeletal muscle actin (Cytoskeleton, Inc.) was ribosylated as
detailed by Margarit, et al. [142]. The ribosylation reaction contained 1mg of
actin, 100ug purified SpvB, and 200μM NAD in a buffer containing 5mM Tris-HCl,
pH 8.0, 0.2mM ATP, 0.2mM CaCl2, and 2mM DTT to a final volume of 1mL. The
reaction was incubated at 4°C for 16 hours with gentle mixing. 100μg SpvB in a
polymerization buffer with a final composition of 50mM KCl, 2mM MgCl2, 0.2mM
ATP was added to the reaction and the mixture was incubated at room
temperature for 2 hours. The reaction was then centrifuged at 100,000xg for 1
hour at 4°C and the supernatant was further purified on a 120mL Superdex 75
column (GE Healthcare) into 5mM Tris-HCl, pH 8.0, 0.2mM CaCl2, 0.2mM ATP,
100mM NaCl, and 2mM DTT. Ribosylated actin eluted as a monomer at
60.18mL.
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Purified SipC200-330 (in 25mM HEPES, pH 7.5, 250mM NaCl, 5mM DTT)
was mixed with ribosylated actin in a 1:1 molar ratio, SipC to actin. The binding
reaction was carried out in the presence of 150mM NaCl at 4°C for 16 hours with
gentle mixing. The reaction was then run over a 120mL Superdex 75 column
(GE Healthcare) in 25mM Tris-HCl, pH 8.0, 0.2mM CaCl2, 0.2mM ATP, 150mM
NaCl, and 2mM DTT.

AI.2.6 Actin Polymerization Assay

Our actin polymerization assay protocol was based on that detailed by
Cytoskeleton, Inc. (Denver, CO) and Machesky, et al. [144]. Pyrene-actin
(Cytoskeleton, Inc.) was diluted to 0.45mg/mL using G-buffer (5mM Tris-HCl, pH
8.0, 0.2mM CaCl2), 0.2mM ATP, and 1mM DTT, and allowed to sit 1 hour on ice.
The pyrene-actin was then centrifuged at 14,000rpm at 4°C for 30 minutes, and
the supernatant, containing monomeric pyrene-actin, was removed for use in
subsequent experiments. 10μM of unlabeled actin (Cytoskeleton, Inc.)
reconstituted in G-buffer was incubated at room temperature for 60 minutes to
induce filament formation. Arp2/3 was diluted to 0.3mg/mL in G-buffer prior to
the start of the reaction.

The assay was performed in a black-bottom 96-well plate (Sigma Aldrich)
at room temperature. Each reaction was performed in a 300μL reaction volume.
200μL of P-buffer (7.5mM Tris-HCl, pH 8.0, 75mM KCl, 3mM MgCl2, and 1.5mM
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ATP) was aliquoted into each well. 0.3μM of pre-incubated unlabeled actin in Gbuffer was added to the reaction, followed by SipC200-409 (0.5μM, 1μM, 2.5μM) in
25mM Tris, pH 8.0, 250mM NaCl, and 5mM DTT, and finally, 0.8μM monomeric
pyrene-actin in G-buffer was added to the reaction. The reaction was shaken
initially to mix and shaken again before each time point was taken. Time points
were taken every 30 seconds for 40 minutes. Excitation was measured at 365nm
and emission was measured at 407nm. Arp2/3 (Cytoskeleton, Inc.) together with
the VCA domain of WASp (Cytoskeleton, Inc.) served as a positive control.
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AI.3 Results and Discussion

AI.3.1 SipC N-terminal Domain

The N-terminal domain of SipC, spanning residues 1 to 120, was found to
be either insoluble or unstable in most of the purification schemes examined.
Purification attempts focused on the following constructs: SipC1-120, SipC5-120, and
a full construct with an additional random seven residues, LERPHRD, inserted
after residue 120, denoted SipC1-120(7+). The SipC5-120 construct was identified by
M. Lilic as a potential minimal construct through limited proteolysis with subtilisin
protease (Sigma Aldrich). GST-tagged SipC1-120 and SipC5-120 were insoluble
(Fig. 19A); however, SipC1-120(7+) was partially soluble and purified material could
be concentrated to 0.67mg/mL before precipitation would occur. This construct
was also sensitive to salt concentration, and would precipitate under low NaCl
(<100mM NaCl) conditions.

Histidine-tagged SipC1-120 was also partially soluble and the protein was
amenable to purification under denaturing conditions and subsequent dialysisbased refolding (Fig. 19A). Using these methods, SipC1-120 was purified with a
total yield of 0.7mg of protein per liter of cell culture grown (Fig. 19B). Crystal
screens were set-up using refolded SipC1-120 at the highest concentration
attainable, 1.83mg/mL. These screens did not lead to successful crystallization.

!

76!

A!
Construct!

Solubility!

GST-SipC(1-120)!

No!

GST-SipC(1-1207+)!

Partially!

GST-SipC(5-120)!

No!

His-SipC(1-120)!

Partially!

His-SipC(5-120)!

No!

Yield!

unstable!

0.7 mg/L!

B!
15.78mL!

01.!

20kD!
%#!
15kD!
$'!
10kD!
$#!

01.!

()*+,-!
!!!!!!!!!!!"#!!!!!"$!!!"%!!!!""!!!!"&!!!"'!
!*)./! %#!
Figure 19. Purification of the N-terminal
domain of SipC. (A) The constructs
$'!
$#!

tested for solubility and stability are listed
along with their respective solubility
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!!!!!!!!!!!"#!!!!!"$!!!"%!!!!""!!!!"&!!!"'!
!*)./!

and yield. (B) The final purification step for refolded SipC1-120 was done on a
25mL Superdex 200 column (GE Healthcare). SipC1-120 runs as a trimer, eluting
at 15.78mL. Lane 1 (far left) contains the molecular weight marker, lane 2 is the
column load material, and the remaining lanes are the fractions corresponding to
the elution peak.
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AI.3.2 SipC C-terminal Domain

AI.3.2.1 Domain Determination and Purification

Our initial SipC C-terminal domain construct spanned residues 200 to 409,
as this was the domain defined in the literature. This construct was purified with
an N-terminal histidine tag as described, and was further purified by size
exclusion chromatography using a Superdex 75 column (GE Healthcare) with a
120mL column volume into 20mM HEPES, pH 7.5, 200mM NaCl, and 5mM DTT
(Fig. 20). Purification using buffers of varying pH were also examined. SipC200409

was most stable in a 6-8 pH range, and purification in Tris-HCl, pH 8.0,

HEPES, pH 7.5, bis-tris-propane, pH 6.8, and MES, pH 5.8 showed similar
protein yields and long-term stability. SipC200-409 showed significant precipitation
when purified in acetate buffer at pH 4.6.

The histidine tag used to purify the SipC200-409 domain was not cleavable
by 3C protease, most likely due to the construct folding in such a way as to
obscure the cleavage site. Therefore, SipC200-409, shown in Figure 20A, contains
the N-terminal histidine tag and runs approximately 7kD larger than it would
without the tag. The His-SipC200-409 construct elutes at 50.18mL, running as a
tetramer, on a 120mL Superdex 75 column (GE Healthcare). A characteristic
banding pattern, consisting of three predominant lower molecular weight bands,
elutes at 57.49mL and was observed in the later stages of purification for the full-
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length C-terminal domain (Fig. 20A). This cleavage may be due to activity of
proteases inherent to E. coli that were still present in the purified material.

A!

B!

Residue!

MW
(kD)!

pI!

Yield!
(mg/L)!

200-409!

23!

9.3!

0.6!

200-374!

18.8!

8.3!

200-330!

14.3!

9.2!

200-320!

13.1!

9.2!

200-308!

11.5!

9.0!

200-300!

10.7!

10.0!

200-295!

10!

9.3!

200-290!

9.6!

9.3!

30kD !

195-400!

23!

9.2!

20kD !

195-295!

10.6!

9.2!

195-278!

8.8!

9.3!

50.81mL!

57.49mL!

50kD !
0.75 !

1.33!

Figure 20. The purification of the C-terminal domain of SipC. (A) Histidinetagged SipC200-409 was purified on a 120mL Superdex 75 column into 25mM
HEPES, pH 7.5, 200mM NaCl, and 5mM DTT. The full-length construct elutes at
50.81mL, and the characteristic cleavage products elute at 57.49mL. Lane 1 (far
left) contains the molecular weight marker, lane 2 is the column load material,
and the remaining lanes are the fractions corresponding to the elution peak. (B)
The C-terminal domain constructs that were produced and screened for
crystallization. Yields are estimates based on comparison to protein of known
concentration by SDS-PAGE because the C-terminal domain of SipC does not
contain enough aromatic residues to contribute to an accurate UV absorbance, or
arginines for meaningful Bradford assay results.
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Limited proteolysis using subtilisin on native SipC200-409 and denatured and
refolded SipC200-409 proved unsuccessful in determining a minimal construct (Fig.
21A), so the cleavage products present during purification were sent to the
Columbia University Protein Core Facility (New York, NY) for Edman sequencing.
N-terminal sequencing indicated that cleavage was occurring C-terminally,
defining constructs starting at residue 200 and ending at residue 360, 330, or 320
(Fig. 21B). C-terminal truncations were estimated based on the molecular weight
of the cleavage products. This information, combined with secondary structure
predictions, led to the construction and purification of SipC200-374 and Sip200-320.
Constructs with various N-terminal starts, at residue 180, 190 and 195, were
screened as well; however, only those beginning with residue 195 were screened
for crystallization. In addition to the constructs listed in Figure 20B, denatured
and refolded SipC200-409 and SipC195-400, as well as reductively methylated
SipC200-409, SipC200-295, SipC200-290, and SipC195-278 were tested for crystallization
ability.
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(200-409)!
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Subtilisin!
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200-360!
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15kD!
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Figure 21. Limited proteolysis of the SipC C-terminal domain. (A) The
subtilisin digestion of His-SipC200-409 was performed at 4°C for 30 minutes using
3.45ng to 11.5ng of subtilisin and 11.5μg of SipC. (B) His-SipC200-409 cleavage
products appeared during purification, and C-terminal cleavage was determined
via Edman sequencing. Corresponding truncations are shown in red. (C)
SipC200-330 was treated with trypsin. The band sent for Edman sequencing is
indicated in red.

Upon removal of the C-terminal 79 residues for the SipC200-330 construct,
3C protease was able to access the cleavage site and the histidine tag was
removed. This suggests that the C-terminus of SipC200-409 was folded towards
the N-terminus of the construct and restricted 3C protease’s access to the
cleavage site. A trypsin digest of SipC200-330 revealed an additional C-terminal
cleavage product corresponding to a construct spanning residues 200 to 320,
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which was estimated based on molecular weight of the cleavage product and the
location of trypsin cleavage sites (C-terminal to arginine and lysine residues) (Fig.
21C). Crystallization trials were set-up with constructs in as high a concentration
as could be obtained, usually between 2-8mg/mL. Higher concentrations could
be attained with the shorter SipC C-terminal domain constructs, and SipC195-278
could be concentrated to 16mg/mL.

We hypothesized that the instability of SipC could stem from exposed
membrane-associated regions still potentially present in our constructs. In an
effort to mask these areas, we investigated whether the addition of 1M guanine
HCl or 1% octyl glucoside (w/v) could enable a higher concentration of SipC200-330
to be achieved. We found that 1% octyl glucoside (w/v) allowed for the
concentration of SipC200-330 to roughly 1.5 times greater than that of the material
concentrated in the presence of 1M guanine HCl and approximately 2 times
greater than material without either additive, suggesting that the addition of a mild
detergent may aid in purification of the SipC C-terminal domain.

AI.3.2.2 Crystallization
SipC200-295 was the largest construct tested that produced crystalline
growth in crystallization trials (Fig. 22). The purification of SipC200-295 was
performed as described, and protein eluted as a tetramer on a 120mL Superdex
75 column (GE Healthcare). SipC200-295 shows little to no UV absorbance due to
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the absence of aromatic residues in the construct. The typical crystal
morphology seen with SipC200-295 consisted of various spherulites and needle-like
clusters that grew in a wide variety of low- to mid-range molecular weight PEG
conditions (Fig. 22B). Further screening with PEG-containing conditions; the
addition of various additives; and reductive methlyation of SipC200-295 did not
improve the crystal morphology.

B!

A!
58.42mL!

64.45mL!

50kD!
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4

20kD!

10kD!

Figure 22. The purification and crystallization of SipC200-295. (A) SipC200-295
elutes at approximately 65mL on a 120mL Superdex 75 column (GE Healthcare).
Lane 1 (far left) contains the molecular weight marker, lane 2 is the column load
material, and the remaining lanes are the fractions corresponding to the elution
peak. (B) Examples of the crystal morphologies seen with SipC200-295.
Crystallization conditions are as follows: (1) 0.8M sodium phosphate/1.2M
potassium phosphate, 0.1M acetate, pH 4.5; (2) 0.2M ammonium sulfate, 0.1M
bis-tris, pH 5.5, 25% PEG 3350; (3) 1M sodium citrate, 0.1M tris, pH 7.0, 0.2M
NaCl; (4) 0.2M sodium cacodylate, pH 6.5, 30% PEG 8000.
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The most promising crystal morphology was obtained with SipC195-278 (Fig.
23A), which produced birefringent needle spherulites (Fig. 23B). Reductive
methylation of the lysine residues of SipC195-278 led to the formation of thicker,
individual needles (Fig. 23C); however, optimization of crystal conditions did not
lead to crystals suitable for X-ray diffraction experiments. Seeding using the
methylated SipC195-278 needles was performed to encourage the growth of larger,
ordered crystals, but also proved unsuccessful.
A!

B!
67.68mL!

C!

15kD!
10kD!

Figure 23. The purification and crystallization of SipC195-278. (A) SipC195-278
was purified on a 120mL Superdex 75 column (GE Healthcare) and eluted as a
trimer at 67.68mL. Lane 1 (far left) contains the molecular weight marker, lane 2
is the column load material, and the remaining lanes are the fractions
corresponding to the elution peak. (B) SipC195-278 produced a birefringent needle
spherulite in 0.2M ammonium citrate, pH 7.0, 20% PEG 3350. (C) Reductively
methylated SipC195-278 produced thicker, individual needles. The growth condition
shown contains 0.1M sodium acetate, pH 4.6, 2M ammonium sulfate.
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AI.3.2.3 Binding Partners

As crystallization of the SipC C-terminal domain by itself did not lead to
diffraction quality crystals, further work was aimed at purifying and crystallizing
SipC in complex with potential C-terminal domain binding partners: ribosylated
actin and mouse Exo70. Crystallization with a binding partner often leads to
stabilization of the protein of interest and can aid in successful crystallization.
The C-terminal domain of SipC is known to polymerize monomeric actin to form
actin filaments [30], so we examined the ability of SipC200-330, our largest stable
SipC C-terminal domain construct, to form a complex with ribosylated actin.
Ribosylated actin was produced by using SpvB, an ADP-ribosyltransferase
effector protein from S. typhimurium [142], to modify monomeric actin with ADPribose, thereby preventing actin polymerization and trapping it in its monomeric
state. ADP-ribosylation does not cause notable conformational change in actin
[142]; therefore, we hypothesized that ribosylated actin could serve as a stable
interacting partner with SipC200-320.

In order to form a complex, SipC200-330 and ribosylated actin were
incubated together as described and run over a 120mL Superdex 75 column (GE
Healthcare). A stable complex was not formed, as ribosylated actin and SipC200330

do not co-elute on the size exclusion column (Fig. 24). It is possible that

complex formation is not favored under the given conditions, or that ribosylated
actin and/or the truncated C-terminal domain are not ideal interacting partners.
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We also do not know how stable an interaction the SipC C-terminal domain has
with monomeric actin. The interaction may only be transient, and as a result,
would not be useful in crystallization studies.

61.34mL!

50kD!
40kD!

20kD!
15kD!

Figure 24. SipC200-330 and ribosylated actin do not form a stable complex.
SipC200-330 was incubated in a 1:1 molar ratio with ribosylated actin for 15 hours
at 4°C, and then run over a 120mL Superdex 75 column (GE Healthcare).
Ribosylated actin is approximately 45kD and elutes as a monomer, separately
from 17kD SipC200-330. SipC200-330 is not detected as a separate peak on the UV
spectrum because it does not contain the aromatic residues necessary to give a
substantial UV absorbance; however, a visible shift between SipC200-330 and
ribosylated actin elution can be detected by SDS-PAGE. . Lane 1 (far left)
contains the molecular weight marker, lane 2 is the column load material, Lane 3
is another molecular weight marker, and the remaining lanes are the fractions
corresponding to the elution peak.
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Nichols, et al. reported that SipC200-409 interacts with the N-terminal
domain of human Exo70 [138]. There are six isoforms of human Exo70, making
in-house cloning of the gene problematic. Additionally, the full-length clone was
not available commercially, so we elected to work with mouse Exo70, a 653
residue homolog that shares a 96% overall identity with human Exo70 but has an
82 residue deletion in the N-terminal domain. M. musculus Exo70 (mExo70) was
soluble and stable when expressed with a large N-terminal tag, so experiments
were performed with either a 63kD 6xHistidine-NusA tag or a 43kD maltosebinding protein (MBP) tag on mExo70.

Various methods for complex formation were investigated. Purified SipC
constructs, 195-400, 200-330, and 200-295, were mixed with purified mExo70
constructs, 1-653 and 85-653, in a 1:1 molar ratio and incubated for 16 hours at
4°C. Stable complex formation was probed by size exclusion chromatography
using a Superdex 200, 120mL column (GE Healthcare). SipC and mExo70 did
not form a complex, and eluted in individual peaks for all construct combinations
analyzed. Co-expression of histidine-tagged SipC200-409 and MBP-tagged
mExo70 was also unsuccessful in forming a stable complex. By co-expressing
SipC200-409 with N-terminally 6x-histidine-NusA tagged mExo7085-653, we were
able to pull-down SipC200-409 from cell lysate using NiNTA resin (Qiagen) (Fig.
25). The complex was not stable in the long-term, as SipC and mExo70 eluted
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separately when run over a Superdex 200, 120mL column (GE Healthcare).
Therefore, crystallization with this complex was not attempted.

IS

lysate FT Wash1 Wash2

Elution!

120kD!
100kD!

His-NusA+mExo70!

60kD!

Cleaved mExo70,!
Free NusA!

50kD!

SipC(200-409)!

20kD!

Figure 25. Pull-down of SipC200-409 by histidine-NusA-tagged mExo7085-653.
Histidine-NusA tagged mExo7085-653 and SipC200-409 were co-expressed and
protein was loaded onto a NiNTA column (Qiagen). The insoluble fraction is
indicated with IS. The column elution contains His-NusA-mExo7085-653 running at
roughly 110kD and untagged SipC200-409 running at about 23kD.
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AI.3.2.4 Actin Polymerization Assay

In order to test our C-terminal domain SipC constructs for their ability to
stimulate actin polymerization, we developed an assay based largely on an actin
polymerization assay kit from Cytoskeleton, Inc. (Denver, CO) as well as the
protocol detailed by Machesky, et al. [144]. The assay is performed with pyrenelabeled actin (Cytoskeleton, Inc.), which emits a greater fluorescent signal when
it is polymerized into F-actin [145]. Pyrene labeling does not alter the critical
concentration of actin or interfere with normal filament formation [133]. We used
Arp2/3 (Cytoskeleton, Inc.) in combination with the VCA domain of human
Wiskott-Aldrich syndrome protein (WASp) (Cytoskeleton, Inc.) for a positive
control of actin polymerization (Fig. 26). The Arp 2/3 complex promotes actin
filament nucleation in eukaryotic cells by binding to existing actin filaments and
creating branch points for further filament formation [146]. Arp2/3 is able to
stimulate rapid actin polymerization when bound to the C-terminal VCA domain
conserved among WASp family members [147, 148]. When Arp2/3+VCA was
added to pyrene-actin, a dramatic increase in pyrene fluorescence was observed
(indicative of actin polymerization), leveling off approximately 10 minutes into the
reaction (Fig. 26).
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Figure 26. SipC200-409 actin polymerization assay. SipC200-409 did not show
actin polymerization activity above the background; however, the positive control,
Arp2/3 + VCA, successfully polymerizes pyrene-actin under the given conditions.
Data shown is the average of two assay runs for each component. Standard error
of the mean indicated with a black bar for each time point. Reaction conditions
detailed in section AI.2.6.
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Our SipC200-409 construct did not show actin polymerization activity above
that detected for actin alone (Fig. 26). We initially performed this assay under the
conditions described by Hayward, et al. [30], but when this proved unsuccessful,
we sought to identify more ideal reaction conditions. Hayward, et al. [30] and
McGhie, et al. [134] used a 1:10 SipC to actin ratio for their polymerization
assays, and the same buffer and assay conditions as are detailed in section
AI.2.6. We investigated a range of SipC to actin ratios, screening our SipC200-409
and SipC195-400 constructs for activity with SipC to actin ratios ranging from 1:100
to 5:1. We also examined different buffer and salt conditions, and tried various
pyrene-actin concentrations, including combinations of pyrene-actin and
unlabeled actin. No activity was detected under any of these reaction conditions.
Urea denatured and refolded SipC200-409 was also tested for activity, and also
gave a negative result. Therefore, we were not able to show actin nucleation
activity with our C-terminal constructs of SipC.
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AI.4 Conclusions

SipC plays an integral part in Salmonella host entry, through its role as a
translocase and through manipulation of the host cytoskeleton via actin
nucleation and filament bundling. We sought to define the structure of SipC in
order to gain an understanding of how this protein is able to perform its many
functions. We investigated the N- and C-terminal effector domains of SipC as
crystallization targets separately, and found that the N-terminal domain, SipC1-120,
could not be purified in its native state, requiring denaturation and refolding in
order to remain soluble in vitro.

The C-terminal domain proved more amenable to in vitro work, and
extensive crystallization screening was performed with different constructs of this
SipC domain. SipC200-295 and SipC195-278 led to spherulite and needle-like crystal
formation in crystallization trials; however, efforts to optimize these initial hits did
not lead to diffraction quality crystals. A fluorescence-based assay was
implemented to test for actin nucleation ability of SipC, although C-terminal
domain constructs did not show activity in this assay. These results are in
contrast to the work published by Hayward, et al., which demonstrated actin
nucleation activity of the SipC C-terminal domain using a similar fluorescencebased approach with refolded SipC200-409 [30]. Our assays were performed with
native SipC200-409 as well as denatured/refolded SipC200-409 under identical
conditions as used by Hayward, et al. [30]. We were not able to replicate their
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experiment under their described conditions, nor were we able to find more
optimal conditions in which to detect actin nucleation activity. One explanation
for this discrepancy is that we used our own protocol for refolding SipC200-409;
however, our refolded material was successfully refolded, as indicated by its
elution profile by size exclusion chromatography, so we believe our protocol was
adequate for proper protein folding. It is still feasible that there were differences
in refolding that might have led to our construct’s inactivity, so further
experimentation will be necessary in order to rule out this possibility.

Further examination of purification conditions for SipC domains could
prove useful for successful crystallization. Despite testing a variety of different
conditions, our SipC constructs always behaved as multimers. There may be a
yet untested set of conditions that could yield monomeric material, potentially
aiding in activity assaying as well as crystallization. Cytokeratin 8 may serve as
a better binding partner for SipC200-409 and this interaction has yet to be confirmed
and probed for crystallization.
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APPENDIX II. AVIRULENCE PROTEIN A
AII.1 Introduction

Salmonella Avirulence Protein A (AvrA) is a SPI-1 encoded effector
protein that is conditionally expressed in enteritis-related Salmonella strains,
such as S. typhimurium [149, 150]. AvrA is a 34kD protein with a high sequence
similarity, and 56% sequence identity, to Yersinia pseudotuberculosis YopJ [151].
AvrA does not appear to be a phenocopy of YopJ, as AvrA and YopJ do not
perform the same functions in host cells and are not interchangeable [152]. AvrA
is predicted to contain a cysteine protease catalytic domain, comprised of
His123-Glu142-Cys186, which is characteristic of Clan CE cysteine proteases
(Fig. 27) [153]. Members of Clan CE are similar to those of Clan CA in that they
both employ the same catalytic mechanism driven by an active cysteine thiol, but
they differ in the arrangement of their triad residues. AvrA is grouped into the
YopJ-like C55 family within Clan CE, which contains members with sumoyl
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peptidase or acetyltransferase activity [113, 154].

Catalytic Domain!

302!

Figure 27. A schematic representation of AvrA and its catalytic domain.
AvrA is 302 residues in length and is hypothesized to contain a catalytic triad of
His123, Glu142, and Cys186. Gln180 aids in the formation of the oxyanion hole
necessary for catalysis.
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AvrA’s involvement in cell infection remains poorly understood, as both
AvrA’s catalytic function and targeted host signaling pathways are unclear. AvrA
does appear to have anti-apoptotic and anti-inflammatory effects on the host, and
potential roles for AvrA include: stabilization of host cell permeability and tight
junctions [149]; inhibition of the NF-κB signaling pathway [155]; counterbalance
of the SPI-I TTSS effector activated JNK pathway and suppression of cell death
[46, 156]. In order to carry out these functions in the host, AvrA has been
attributed with having deubiquitinase and acetyltransferase activity.

Deubiquitinases are cysteine proteases that cleave ubiquitin-protein
bonds, preventing degradation of the targeted proteins. Potential substrates of
AvrA catalyzed deubiquitination are NF-κB, IκBα, β-catenin, and Wnt2 [46, 157,
158]. Acetyltransferases, also commonly cysteine proteases, are responsible for
the transfer of actyl groups to specific residues on their target protein. AvrA Oacetylates a key threonine residue located in the activation loop of MAPK kinase
4, inhibiting JNK and subsequently leading to the attenuation of the host
inflammatory response [159]. Through acetylation of p53, AvrA activates the p53
pathway to stimulate cell cycle arrest and block apoptosis [160]. Inositol
hexakisphosphate, a eukaryotic host cell factor, has been shown to stimulate
AvrA’s acetyltransferase activity in vitro and is believed to serve as an allosteric
activator of AvrA [161]. We sought to determine the X-ray structure of AvrA in
order to gain a more precise understanding of its role in Salmonella infection.
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AII.2 Materials and Methods

AII.2.1 Protein Expression and Purification

All AvrA constructs were amplified from Salmonella Typhimurium strain
SL1344, and inserted into a modified pCDF-Duet-1 vector (Novagen) between
the SalI and NotI restriction sites. The catalytically inactive mutant, AvrAC186A,
was generated by point mutagenesis. Protein was expressed in E. coli
BL21(DE3) cells with 1mM IPTG for 16 hours at 21°C. Harvested cells were
pelleted, resuspended in 50mM HEPES, pH 7.5, 300mM NaCl, and 5mM
imidazole, and lysed via high-pressure homogenization. Cleared lysate was run
over Ni-NTA resin (Qiagen) and protein was eluted in 50mM HEPES, pH 7.5,
300mM NaCl, and 500mM Imidazole. Protein was dialyzed against 25mM
HEPES, pH 7.5, 250mM NaCl, and 5mM DTT, and the N-terminal histidine tag
was cleaved off with 6xHis-rhinovirus 3C protease. The material was passed
over Ni-NTA to remove the histidine tag and 3C protease. The final purification
step was size exclusion chromatography using a Superdex 75 column with a
120mL resin volume (GE Healthcare). All AvrA constructs were purified into
25mM HEPES, pH 7.5, 250mM NaCl, and 5mM DTT.

ARFGEF2 constructs were cloned out of human cDNA extracted from
breast cancer cells (generously provided by L. Fish). PCR products were
inserted between SalI and NotI restriction sites in a modified pGEX4 vector (GE
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Healthcare) that was engineered to contain a 6xHistidine tag followed by a
rhinovirus 3C protease cleavage site all 3’ to the GST tag. For co-expression of
AvrA and ARFGEF2, ARFGEF2 was cloned between the SalI and NotI restriction
sites of a modified pCDF-Duet-1 vector (Novagen) and AvrA was inserted
between the NdeI and XhoI restriction sites. Co-expression was also performed
with AvrA in the first cloning site between SalI and NotI and ARFGEF2 in the
second site between NdeI and XhoI. Purification of ARFGEF2 alone and in
combination with AvrA was performed as described for AvrA by itself.

AII.2.2 Limited Proteolysis
Limited proteolysis on 31.5μg of AvrA63-302 was performed using subtilisin
protease (Sigma Aldrich), ranging from 3.25ng to 1.89μg, with 5mM CaCl2. The
reaction was allowed to proceed at room temperature for 20 minutes, and was
stopped with the addition of 10mM PMSF and SDS loading buffer. Reaction
products were separated via 15% SDS-PAGE and were transferred to PVDF
membrane (Millipore) for visualization by SYPRO® Ruby protein stain (Sigma
Aldrich). Major cleavage product bands were excised from the membrane and
sent to the Columbia University Protein Core Facility (New York, NY) for Nterminal Edman degradation sequencing.
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AII.2.3 Yeast Two-Hybrid Sample Preparation
AvrA15-302 and catalytically inactive AvrA15-302, C186A were cloned into the
pGBT9 vector (Clontech Laboratories, Inc.) between the EcoRI and SalI
restriction sites. The vectors containing the AvrA bait constructs were sent to the
Protein Interaction Screening department of the Genomics and Proteomics Core
Facility at the German Cancer Research Center (Heidelberg, Germany) for yeast
two-hybrid screening. A pre-screen with varying 3-aminotriazole concentrations
was performed using both wild-type and the catalytic mutant of AvrA15-302. It was
determined that AvrA15-302, C186A could be screened at a higher stringency with
positive hits clearly above the background, so the catalytic mutant was used in
four independent screens using a human universal normalized cDNA library with
0mM 3-aminotriazole.
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AII.3 Results and Discussion

AII.3.1 Domain Determination and Purification

In order to obtain a structure of AvrA, we tested various constructs for their
crystallization propensity (Table 5). Full-length AvrA was poorly soluble, but it
was it was found that expression of AvrA15-302 led to a significantly higher protein
yield. Limited proteolysis of AvrA15-302 using subtilisin protease identified new
constructs with further N-terminal truncations, AvrA27-302 and AvrA63-302. Of the
constructs screened, AvrA63-302 provided the greatest yield of 14.2mg of protein
per liter of culture grown. Treatment of AvrA63-302 with subtilisin protease
revealed C-terminal truncations at residues 275, 258, and 244, estimated based
on molecular weight of the cleavage products (Fig. 28). Additional C-terminal
truncations, at 220 and 214, resulted in insoluble constructs.

Table 5. AvrA constructs produced for crystallization.
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1-302!

33.7!
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Y!
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32!
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27!
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20.5!
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10.8!

63-220!
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Figure 28. Limited proteolysis of AvrA63-302. AvrA63-302 was treated with
subtilisin protease, ranging from 3.25ng to 1.89μg, for 20 minutes at room
temperature. There were three main cleavage products, all of which were the
result of C-terminal cleavage. The products correspond to construct of 63-275,
63-258, and 63-244.

AvrA63-244 was soluble with an N-terminal histidine tag, and yielded
approximately 10.8mg of protein per liter of culture grown. The final step in the
purification of this construct is shown in Figure 29. On the Superdex 75, 120mL
column under the given conditions, AvrA63-244 runs as both a dimer and
monomer, eluting at 61.16mL and 70.58mL, respectively. Crystal screens were
performed using the monomeric material, but did not lead to crystals. None of
the AvrA constructs successfully crystallized; therefore, we attempted to find a
binding partner that would aid in crystallization.
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Figure 29. The purification of AvrA63-244. AvrA63-244 was purified on a
Superdex 75, 120mL column (GE Healthcare) into 25mM HEPES, pH 7.5,
250mM NaCl, and 5mM DTT. There are two elution peaks, corresponding to
elution as a dimer (61.16mL) and as a monomer (70.58mL). Lane 1 (far left)
contains the molecular weight marker, lane 2 is the column load material, and the
remaining lanes are the fractions corresponding to the elution peak.

AII.3.2 ARFGEF2: A Potential Binding Partner

To identify a potential binding partner for AvrA, we contracted with the
Genomics and Proteomics Core Facility at the German Cancer Research Center
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(Heidelberg, Germany) to perform a yeast two-hybrid screen using catalytically
inactive AvrA15-302, C186A as bait. A yeast two-hybrid screen is a method for
probing the interaction between two proteins. The protein of interest is used as
the bait, and is expressed in yeast cells containing a prey plasmid generated
from a cDNA library that is derived from the organism or tissue of choice.

Table 6. Yeast two-hybrid results. AvrA15-302, C186A was used as bait in four
independent yeast two-hybrid screens against a human universal normalized
cDNA library.
Prey!

No. of times
prey has
been
isolated!

No. of
times
fragment
starts in 5’
UTR!

No. of
times
fragment
starts in 3’
UTR!

No. of times
fragment
starts in
coding
sequence!

Avg. No. of
bases of 5’
UTR in prey
sequence!

Prey
promiscuity !

ARFGEF2!

3!

0!

0!

3!

0!

1!

ASAP1-IT1!
(non-protein)!

2!

0!

0!

2!

0!

2!

ANK3!

2!

2!

0!

0!

618!

5!

Four independent screens were executed against a human universal
normalized cDNA library at the lowest stringency level possible using 0mM 3aminotriazole. Three prey proteins were identified as potential interacting
partners with the catalytically inactivate AvrA15-302: Brefeldin A-inhibited Guanine
Nucleotide Exchange Protein 2 (ARFGEF2); ASAP1 intronic transcript 1 (ASAP1IT1); ankyrin 3, node of Ranvier (ANK3). The results are summarized in Table 6.
ANK3 was isolated two times in the screening process; however the isolated
fragments were all located in the 5’ untranslated region (UTR). ASAP1-IT1 was
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likely an artifact as it is a non-protein coding sequence. ARFGEF2 was the most
promising result of this experiment. ARFGEF2 was isolated in three out of the
four screens, and in all three instances, the isolated fragment started in the
coding sequence of the protein. ARFGEF2 also had a prey promiscuity of 1,
which indicates that this bait/prey pair is highly specific.

The isolated fragment of ARFGEF2 corresponds to the C-terminal domain
of the protein, spanning residues 1638 to 1786. ARFGEF2 is a large, 200kD
guanine nucleotide exchange factor that is required for vesicle trafficking from the
trans-Golgi network [162]. ARFGEF2 stimulates the exchange of GDP for GTP
to activate ADP-ribosylation factors (ARFs), which then assemble coat proteins
around intracellular vesicles, mediating vesicle cycling between the trans-Golgi
network, endosome, and plasma membrane [163, 164]. The nucleotide
exchange activity of ARFGEF2 is attributed to the presence of a Sec7 domain,
correlating to residues 644 to 832 (Fig. 30A). The Sec7 domain was originally
identified in yeast and is highly conserved in proteins possessing GEF activity
[165]. ARFGEF2 has also been found to associate with recycling endosome-like
peripheral vesicles and has been implicated in the coordination of actin
cytoskeleton mechanics and membrane traffic in cell migration via an interaction
with integrin β1 [166]. The C-terminal domain of ARFGEF2 has not been
associated with a specific function; however, it is possible that AvrA’s interaction
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with this domain could affect ARFGEF2’s role in vesicular transport and/or in
actin cytoskeleton dynamics to aid Salmonella in evading the host defenses.
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Figure 30. The AvrA interacting domain of ARFGEF2 and its purification.
Through a yeast two-hybrid screen, the C-terminal domain of ARFGEF2,
residues 1638 to 1786 (orange), was identified as a potential binding partner of
AvrA15-302, C186A. (A) ARFGEF2 is 1786 residues in length and contains a Sec7
domain. The initial ARFGEF2 constructs designed to probe for AvrA interaction
had N-terminal starts at residues 1490, 1510, and 1520, respectively, and all
ended at residue 1786. (B) ARFGEF2 constructs were expressed with Nterminal GST-6xHis tags, running at approximately 55-60kD. All constructs were
found in the insoluble fraction, which is denoted as IS, the soluble fraction as S,
and the Ni-NTA elution as Eln. The first lane on each gel (far left) contains the
molecular weight marker.
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In order to confirm the interaction between AvrA and the C-terminal
domain of ARFGEF2, we designed three ARFGEF2 constructs based on
secondary structure predictions generated by Phyre [167]. Constructs started at
residue 1490, 1510, and 1520, and all terminated with residue 1786 (Fig. 30A).
These constructs were expressed with an N-terminal GST-6xHis tag and purified
over a Ni-NTA column (Fig. 30B). All constructs were insoluble.

We also investigated the complex formation between AvrA and ARFGEF2
by co-expressing AvrA15-302, C186A and ARFGEF2 on separate plasmids, pCDFDuet-1 (Novagen) for AvrA and pGEX4 (GE Healthcare) for ARFGEF2, in the
same E. coli cells. Expression was seen for AvrA15-302, C186A, but not for
ARFGEF2. Co-expression from the same vector, pCDF-Duet-1 (Novagen), was
also examined, looking at His-tagged ARFGEF2 with untagged AvrA15-302, C186A as
well as His-tagged AvrA15-203, C186A with untagged ARFGEF2. His-tagged AvrA15302, C186A

was soluble and could be purified on Ni-NTA resin, while untagged

ARFGEF2 remained insoluble.
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AII.4 Conclusions

We have defined a minimal domain of AvrA, which spans residues 63 to
244, and contains the predicted catalytic triad of AvrA. Although under the given
purification conditions, AvrA63-244 was not successful in crystallization trials, more
work can be done to refine the purification conditions and identify those in which
the protein behaves in a uniform state in solution, either as a dimer or a
monomer. Through a yeast two-hybrid screen, we found the C-terminal domain
of ARFGEF2, residues 1638 to 1786, to be a potential interacting partner of AvrA.
Although co-expression of ARFGEF2 C-terminal domain constructs with AvrA did
not yield an AvrA-ARFGEF2 complex, it may prove successful to purify the GSTHis-ARFGEF2 constructs under denaturing conditions, refold, and then probe for
binding to AvrA15-302, C186A. The interaction could also be examined through coimmunoprecipitation or an in vivo immunofluorescence experiment.
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